[go: up one dir, main page]

USRE42961E1 - Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects - Google Patents

Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects Download PDF

Info

Publication number
USRE42961E1
USRE42961E1 US11/046,676 US4667605A USRE42961E US RE42961 E1 USRE42961 E1 US RE42961E1 US 4667605 A US4667605 A US 4667605A US RE42961 E USRE42961 E US RE42961E
Authority
US
United States
Prior art keywords
atrial
effects
nervous system
arrhythmias
parasympathetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US11/046,676
Inventor
Marc Mounir Rahme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Medical Atrial Fibrillation Division Inc
Original Assignee
St Jude Medical Atrial Fibrillation Division Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Medical Atrial Fibrillation Division Inc filed Critical St Jude Medical Atrial Fibrillation Division Inc
Priority to US11/046,676 priority Critical patent/USRE42961E1/en
Assigned to ST. JUDE MEDICAL, ATRIAL FIBRILLATION DIVISION, INC. reassignment ST. JUDE MEDICAL, ATRIAL FIBRILLATION DIVISION, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ST. JUDE MEDICAL, DAIG DIVISION, INC.
Application granted granted Critical
Publication of USRE42961E1 publication Critical patent/USRE42961E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114—Cardiac control, e.g. by vagal stimulation

Definitions

  • Cardiac rhythm disturbances are a major cause of morbidity and even mortality in our ageing population. Most of these rhythms are based on reentry, i.e. the continuous circulation of a wavefront of excitation around a functional or anatomical circuit such atrial fibrillation and flutter. Atrial fibrillation could exist as a stable state, self-sustained and independent of its initiating trigger in the presence of non-uniform distribution (i.e. dispersion) of atrial refractory periods. In addition, maintenance of atrial fibrillation may require a critically short wavelength in order to sustain reentry. However, the cellular and pathophysiological mechanisms in the initiation and maintenance of atrial fibrillation remain poorly understood.
  • the excitable gap is one of the determinant of the continued circulation of the abnormal atrial impulse and in its presence an extrastimulus may excite the circuit and reset the tachycardia.
  • the persistent circulation of this wavefront is determined by the effective refractory period, the conduction velocity, the wavefront and the nature and duration of the excitable gap, i.e. that portion of the circuit which has partially or fully recovered its excitability.
  • This excitable gap in part, determined by the size of the reentry circuit and the electrophysiological properties of its tissue components.
  • Atrial fibrillation In man, the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night which correlates with an immediately preceding increase in vagal drive.
  • Catecholamine administration also shortens the atrial action potential and stimulation of sympathetic nerves shortens atrial refractoriness and increases its dispersion facilitating the induction of atrial fibrillation.
  • attacks of atrial fibrillation have also been reported to be associated with adrenergic activation.
  • antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems. These drugs are either incompletely effective, may have proarrhythmic properties, and also may increase mortality. Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties, there has been increased interest in class III drugs, which act by increasing action potential duration and refractoriness without blocking sodium channels. The pharmacological control of cardiac arrhythmias using class III antiarrhythmic drugs which prolong the cardiac action potential has gained interest recently, particularly in view of reports of proarrhythmic and increased mortality associated with the use of class I antiarrhythmic drugs in the treatment of both ventricular and atrial arrhythmias.
  • drugs with class III antiarrhythmic action may be more effective than the class I antiarrhythmic drugs for conversion and suppression of some cardiac arrhythmias, particularly those due to reentry.
  • This greater efficacy of the class III antiarrhythmic drugs may be due in part to their ability to selectively prolong refractoriness and wavelength and reduce dispersion of refractoriness.
  • Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms.
  • d,l-Sotalol the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current (I ks and I kr ) and thus increases the atrial action potential duration and the atrial effective refractory period. At high concentrations, Sotalol can also inhibit the background or inward rectifying K + (I kl ) and decreases the transient outward K + current (I to ).
  • the purpose of this invention is to determine the effects of norepinephrine and acetylcholine on the excitable gap composition during a sustained stable atrial flutter, and on the atrial effective refractory period duration and dispersion, atrial conduction velocity and atrial wavelength. Furthermore, this invention illustrates also the influence of autonomic nervous system activation and neurotransmitters infusion on the occurrence of these atrial arrhythmias, and whether these significant effects could alter those of sotalol on the same electrophysiological parameters. This invention also project the possibility for new atrial targets for the use of catheter ablation during the treatment of atrial arrhythmias. These new targets for catheter ablation during an atrial arrhythmia may be the fully excitable tissue, and/or the areas with the greatest density of parasympathetic innervation such as the tissues near the sinoatrial nodal fat pad and septal.
  • Atrial arrhythmias a major contributor to cardiovascular morbidity, are believed to be influenced, activated and aggravated by autonomic nervous system tone. Furthermore, the treatment of this atrial arrhythmias are influenced, threaded and degenerated to a proarrhythmic events under the dominant effects of the autonomic nervous system activation.
  • This invention evaluated the significance of sympathetic and parasympathetic activation by determining the effects of norepinephrine and acetylcholine on the composition of the excitable gap during a stable sustained atrial flutter, on the effective refractory period, on the conduction velocity, and on the wavelength in a canine model of stable atrial flutter.
  • Atrial flutter model was produced during baseline conditions around the tricuspid valve using a Y-shaped lesion in the intercaval area extending to the right atrial appendage. Atrial flutter was induced at the shortest effective refractory period site using fast pacing stimulation (S1S1) of 100-150 ms. This manoeuvre was repeated as much as necessary with more damage in the Y-shaped lesion model to achieve a sustained stable atrial flutter (>10 min) during the baseline conditions.
  • S1S1 fast pacing stimulation
  • Atrial fibrillation was induced by fast pacing and up to 10 attempts of arrhythmia initiations during baseline condition, vagal denervation, right and left vagal stimulation #1 (1 Hz, 0.1 ms), right and left stellar ganglions denervation, right and left vagal stimulation #2 (1 Hz, 0.1 ms), right and left stellar ganglions stimulation (10 Hz, 2 ms), and right and left vagal stimulation (1 Hz, 0.1 ms) associated with right and left stellar ganglions stimulation (10 Hz, 2 ms).
  • Atrial fibrillation occurrence was evaluated by the mean duration of 10 atrial fibrillation episodes at baseline (for a group of animals when none of the 10 atrial fibrillation episodes at baseline were lasting more than 3 minutes) and following each of the conditions described above.
  • both neurotransmitters infusions significantly increased the occurrence of the initiation of atrial flutter and decreased the duration of its maintenance by rapid (less than 2 minutes) conversion to a non sustained atrial fibrillation and then to a sinus rhythm state.
  • Both neurotransmitters significantly increased the safety margin of excitability ahead of the wavefront and decreased the effective refractory.
  • Autonomic and, in particular, vagal effects significantly diminish the action of pure class III antiarrhythmic drug, d-sotalol.
  • d,l-sotalol a class III combined with anti-adrenergic effects, only acetylcholine still completely reversed its electrophysiological effects.
  • this invention targets the areas with the greatest density of parasympathetic innervation for ablation, such as the areas located near the sinoatrial nodal fat pad and septal, for the treatment of atrial arrhythmias during a catheter ablation manner.
  • the main purpose of this invention was to study the significant effects of autonomic nervous system on the atrial electrophysiologic parameters related to the pre-conditioning, initiation, persistence and termination of atrial fibrillation and flutter. Furthermore, this invention evaluated whether the significant effects of autonomic nervous system on the atrial electrophysiological parameters and on the occurrence of atrial arrhythmias could change those of class III antiarrhythmic drugs.
  • the effects of sympathetic neural activity on the heart are gradually developed and receded, whereas the inhibitory effects of vagal activity appear and disappear rapidly.
  • the automatic cells in the heart respond promptly to vagal stimulation within a steady-state value of two cardiac cycles.
  • the ability of the vagus nerves to regulate heart rate beat by beat could be explained by the speed at which the neural signal is rapidly transduced to a cardiac response and by also by the rapidity of the processes that restore the basal heart rate when vagal activity ceases.
  • the mechanisms of this rapid development of vagal effects on heart rate will be related to: 1) the acetylcholine regulated potassium channels; 2) the hyperpolarization activated channels, which conduct the If current; and 3) the calcium channels.
  • the acetylcholine and the If channels could both respond rapidly to vagal activity.
  • the If and Ica channels are directly involved in generating the slow diastolic depolarisation in sinus node cells.
  • the release of acetylcholine interacts with cardiac muscarinic receptors that are coupled to its regulated potassium channels directly through G proteins without an interaction of a slow second messenger system. These potassium channels are fully activated by this release of acetylcholine within a few milliseconds.
  • the relatively slow development of the sympathetic responses has been attributed mainly to the inclusion of a second messenger system, notably the adenylyl cyclase system, in the cascade of events that transduce the neuronal release of norepinephrine into a change in cardiac performance.
  • the chronotropic response of the heart to sympathetic activation is mediated mainly via several types of ion channels, such as Ica and If currents.
  • This second messenger system is too slow to permit beat-by-beat regulation of cardiac function.
  • the norepinephrine released from the sympathetic nerve endings is removed from the cardiac tissues much more slowly than is the acetylcholine that is released from the vagal terminals.
  • the atrial tissue and the related ionic currents (Ica, If) are submitted to the sympathetic neural activity after a certain delay of ganglion stellar stimulation.
  • the on-set effects of sympathetic stimulation are considered in the presence of existing vagal stimulation effects on atrial tissue and not in the on-set of this vagal stimulation effects.
  • vagal stimulation or acetylcholine application to the heart can produce either atrial flutter or fibrillation, and can nonuniformly shorten atrial refractoriness periods, thus increasing the regional differences in atrial refractory period.
  • the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night.
  • spectral analysis of heart rate variability has suggested an increase in vagal drive immediately preceding the onset of atrial arrhythmia.
  • Sympathetic stimulation or administration of catecholamines can also influence atrial electrophysiological properties.
  • Isoproterenol shortens the atrial action potential and stimulation of sympathetic nerves shortens slightly atrial refractory period and can facilitate induction of atrial fibrillation. Furthermore, in man, attacks of atrial fibrillation have stellar ganglions produces localised shortening of the refractory period, increases the dispersion of refractoriness and increases the vulnerability to re-entrant arrhythmias.
  • Atrial fibrillation starts with a period of rapid ectopic activity that may be caused by discharge of an autonomic focus, or afterpotentials, particularly in the setting of an enhanced catecholamine state.
  • Vagal tone stimulation initiates atrial fibrillation by hyperpolarization in the atrial tissues and fibres, an effect that does not favor either delayed afterdepolarization or pacemaker activity.
  • the duration of the P waves may actually become shorter than the time required to excite the whole atria.
  • factors may also be the conditions for the perpetuation or the termination of those re-entrant atrial arrhythmnias.
  • Clinical paroxysmal atrial arrhythmias suggesting a predominant vagal mechanism often display a pattern of atrial fibrillation with alternates of atrial flutter.
  • atrial fibrillation dependent of adrenergic activity is most likely related to ectopic automatic foci explained by their ECG appearance.
  • Atrial fibrillation a reentrant arrhythmia, is more likely to occur in the presence of an abnormally shortened atrial effective refractory period and increased dispersion of the effective refractory period.
  • abnormally depressed conduction velocity and anatomic obstacles may play a role in the reentrant mechanism of atrial fibrillation.
  • Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms. Both isomers have equal class III activity but only the l-isomer possesses significant ⁇ -adrenoceptor blocking activity. d,l-Sotalol, the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current (I ks and I kr ) and thus increases the atrial action potential duration and the atrial effective refractory period.
  • I ks and I kr delayed rectifier potassium current
  • sotalol can also inhibit the background or inward rectifying K + (I kl ) and decreases the transient outward K + current (I to ).
  • I kl background or inward rectifying K +
  • I to transient outward K + current
  • autonomic fibers may be non homogeneously distributed in the atrium and this distribution is different for the vagal and sympathetic systems.
  • the latency time and duration of the physiological response are also different. This may contribute to a discrepancy between the effects of neurotransmitter infusion, which may produce a more homogeneous effect compared to the non homogeneous autonomic fiber stimulation.
  • the effects of neurotransmitter infusion may differ from the effects of autonomic fiber stimulation.
  • vagal stimulation inhibits the release of norepinephrine at sympathetic nerve terminals; (2) sympathetic stimulation releases neuropeptide Y, which in turn interferes with the actions of vagal stimulation, possibly by inhibiting the release of acetylcholine; (3) ⁇ -adrenergic stimulation with phenylephrine attenuates the bradycardia induced by direct vagus nerve stimulation; and (4) acetylcholine antagonizes the intracellular production of cyclic AMP by catecholamines. Therefore, the effects we observe with infusion of acetylcholine and norepinephrine likely do not reproduce quantitatively the effects of autonomic nerve activity. Nevertheless, these qualitative effects demonstrate an important modulation of atrial flutter excitable gap which can be clinically significant.
  • Atrial Flutter protocol All experiments described were in accordance with institutional guidelines for animal experimentation. Fourteen mongrel dogs of either sex, weight 29-45 kg, were studied in the post-absorptive state. General anaesthesia was induced with sodium thiopental (25 mg/kg iv.) and maintained with chloralose (80 mg/kg iv. bolus supplemented by 20 mg/kg/hr maximum as needed). The dogs were intubated and ventilated (Harvard pump) with room air (10 breaths/min, tidal volume to achieve a maximum inspiratory pressure of 20 cm water) to maintain arterial pH 7.35-7.45 and PaO 2 >80 mm Hg.
  • Arterial and venous cannulae were inserted in the left femoral artery and vein by direct cut down for blood pressure monitoring and drug administration, respectively.
  • An additional venous cannulae was inserted in the right femoral vein or in the right internal jugular vein for blood sampling.
  • Muscular relaxation was then induced with gallamine triethiodide (Flaxedil 100) 3 mg/kg intravenously.
  • a right thoracotomy was performed via the fourth or fifth intercostal space and the pericardium was incised to provide access to the vena cava and the right atrium.
  • Atrial flutter was induced by burst stimulation (20-30 beats at basic cycle length ⁇ 100 ms). During stable flutter (cycle length variation ⁇ 10 ms), a premature stimulus was introduced at the site located on this re-entry circuit after every 20th spontaneous beat (T) in 2 ms decrements beginning at coupling intervals equal to the cycle length of this atrial tachycardia.
  • the interval between the last spontaneous beat and the response to the subsequent premature stimulus (Coupling Interval) as well as the interval between the response to the premature stimulus and the subscript (T 1 ) tachycardia beat (Return Cycle) were measured (peak-to-peak) at the electrode distal to the stimulating site (in the direction of wavefront propagation). Measurements were made at a paper speed of 100 mm/s using a Digimatic Caliper (Mitutoyo Corporation, Tokyo) which has a resolution of 0.01 mm.
  • the duration of the flat portion was then taken from the intersection of this line with a horizontal line drawn at the flutter cycle length on the ordinate.
  • the excitable gap was characterized by the reset-response technique as previously described by Derakhchan et al. (1994). It assumes that the reentry circuit is located in the muscle ring immediately above the tricuspid valve as has been previously demonstrated (Frame et al., 1986) and that its location in the presence of drug is unchanged.
  • Atrial Fibrillation protocol Fourteen mongrel dogs weighing 19-30 kg were anaesthetised with morphine (2 mg/kg i.m.) and ⁇ -chloralose (100 mg/kg iv.) and ventilated by a respirator (NSH 34RH, Harvard Apparatus, South Natick, Mass.) via an endotracheal tube at a rate of 20-25 breaths per minute with a tidal volume obtained from a nomogram. Arterial blood gases were measured to ensure adequate oxygenation (SaO2>90%) and physiological pH (7.38-7.45). Body temperature was maintained with a homiothermic heating blanket.
  • Catheters were inserted into the left femoral artery and both femoral veins and kept patent with heparinized saline solution (0.9%). A median sternotomy was performed, an incision was made into the pericardium extending from the cranial reflection to the ventricular apex, and a pericardial cradle was created. A pair of Teflon-coated stainless steel bipolar hook electrodes, one for stimulation and the other for recording atrial electrograms, were inserted intramural into the tip of the right atrial appendage.
  • the position of the stimulating electrodes were located in the right atrial appendage (RA-1), left atrial appendage (LA-2), inferior vena cava (IVC-3), medial vena cava (MVC-4) and superior vena cava (SVC-5).
  • a programmable stimulator and a stimulus isolator (Bloom Assoc., Flying Hills, Pa.) were used to deliver 4-msec square-wave pulses.
  • Operational amplifiers (Bloom Association) and a Mingograp T-16, 16 channel recorder (Siemens-Elema Ltd., Toronto, Canada) were used to record the six standard surface electrocardiogram leads, arterial pressure, and stimulus artifacts. Electrocardiographic recordings were obtained at a paper speed of 200 mm/sec.
  • Activation Mapping Five thin plastic sheets containing 112 bipolar electrodes with 1 mm interpolar and 6 mm interelectrode distances were sewn into position on atrial epicardial surface. One sheet was placed under the root of aorta to cover the anterior aspect of the atrial appendages and Bachman's bundle. Three sheets were sewn to the posterior aspects of the atrial appendages and to the free walls. The parietal pericardium was gently separated, and a fifth plaque was placed between the pulmonary arteries and veins. Each signal was filtered (30 to 400 Hz), digitized with 12-bit resolution and 1-KHz sampling rate, and transmitted into a microcomputer (model 286, Compaq Computer, Houston, Tex.).
  • the left and right stellar ansae were stimulated with square-wave pulses of 2 ms duration, 10 Hz frequency and 6 volts. Adequate stellar stimulation was verified by an increase in arterial systolic/diastolic pressure (from the left side) and in heart rate (from the right side). Bilateral vagal nerve stimulation was delivered by an SD-9F stimulator (Grass Instruments, Inc., Quincy, Mass.), with a pulse width of 0.1 msec and a frequency of 1 Hz, with an amplitude of stimulation of 3-10 V, adjusted in each dog to two thirds of the threshold for the production of asystole under control conditions.
  • SD-9F stimulator Gramss Instruments, Inc., Quincy, Mass.
  • At a constant basic cycle length of 200 ms we have determined the effective refractory period duration and the conduction velocity at baseline, vagal and sympathetic denervation. Fifteen seconds after the initiation of vagal (1 Hz, 0.1 ms) and sympathetic stimulation (10 Hz, 2 ms), we started to determine the effective refractory period and conduction velocity duration. Atrial fibrillation initiations were determined by short burst (1-3 seconds) of atrial pacing at a cycle length of 60-100 ms and with a current amplitude of four times the diastolic threshold for atrial capture.
  • Atrial fibrillation duration was determined by the mean of 10 atrial fibrillation episodes during baseline conditions, vagal denervation, vagal stimulation (1 Hz, 0.1 ms) during 3 minutes, sympathetic denervation, vagal stimulation (1 Hz, 0.1 ms) during 3 minutes, and on the combined vagal (1 Hz, 0.1 ms) and sympathetic (10 Hz, 2 ms) stimulation during 3 minutes. If the duration of any atrial fibrillation episode on vagal or sympathetic stimulation was >3 minutes, no further stimulation are required. Animals with atrial fibrillation duration episodes >3 minutes at baseline conditions are excluded from this study.
  • the characteristics of the atrial flutter circuit are detailed in Table 1 from 6 animals. Both norepinephrine and acetylcholine infusion significantly shortened the effective refractory period duration. However, only acetylcholine infusion significantly shortened the atrial flutter cycle length and the excitable gap duration. In the presence of pure class 3 antiarrhythmic drug, d-sotalol, both norepinephrine and acetylcholine significantly reversed the effects of d-sotalol on the atrial flutter cycle length and on the effective refractory period duration, but only acetylcholine infusion significantly reversed d-sotalol effects on the excitable gap duration.
  • the characteristics of the atrial flutter circuit are detailed in Table 2 from 7 animals.
  • Acetylcholine infusion significantly decreased the effective refractory period duration and increased the excitable gap duration.
  • acetylcholine significantly reversed d,l-sotalol effects on the atrial flutter cycle length, on the effective refractory period and on the excitable gap duration.
  • Vagal denervation effects compared to the baseline conditions, significantly decreased the atrial as fibrillation duration, the effective refractory period dispersion and the conduction velocity, and significantly increased the effective refractory period duration.
  • Sympathetic denervation did not significantly changed the effects produced by the vagal denervation.
  • sympathetic stimulation significantly reversed the effects of autonomic denervation on the atrial effective refractory period duration.
  • vagal stimulation before and after sympathetic denervation significantly reversed the effects of autonomic denervation on the atrial fibrillation duration, on the effective refractory period duration and dispersion and on the conduction velocity.
  • Vagal stimulation effects compared from baseline conditions significantly increased the atrial fibrillation duration and the conduction velocity, and significantly decreased the effective refractory period duration.
  • the combined effects of sympathetic-parasympathetic stimulation compared to those of parasympathetic stimulation alone were significantly different only on the conduction velocity, however, these combined effects compared to those of sympathetic stimulation alone are significantly different on the effective refractory period duration and dispersion and on the conduction velocity.
  • AFICL atrial flutter cycle length
  • EEP dur effective refractory period duration
  • EG dur excitable gap duration
  • AF1CL atrial flutter cycle length
  • ERP dur effective refractory period duration
  • EG dur excitable gap duration
  • AF dur atrial fibrillation duration
  • ERP dur effective refractory period duration
  • ERP disp effective refractory period dispersion
  • CV conduction velocity
  • WL wavelength
  • ERP dur and ERP disp are expressed in ms, CV in cm/s, WL in cm, AF dur in s.
  • ERP dur , ERP disp and CV are determined at a basic cycle length (S1S1) of 200 ms, AF dur are determined from the mean duration of 10 AF after its initiations.
  • S1S1 basic cycle length
  • V + S Atrial Fibrillation duration
  • Bas Baseline conditions
  • CV Conduction Velocity
  • ERP dur Effective Refractory Period duration
  • ERP disp Effective Refractory Period dispersion
  • V-D Vagal Denervation
  • V1-S1 Vagal Stimulation at 1 Hz before sympathetic denervation
  • V + S)-D Autonomic Nervous System (Vagal and Sympathetic) Denervation
  • S-S10 Sympathetic Stimulation at 10 Hz
  • V 2 -S1 Vagal Stimulation at 1 Hz after right and left stellar ganglions Denervation
  • V-S1) + (S-S10) Vagal Stimulation at 1 Hz combined with Sympathetic Stimulation at 10 Hz
  • WL Wavelength.
  • Parasympathetic system nervous denervation significantly decreased the occurrence of atrial fibrillation.
  • the activation of parasympathetic nervous system significantly increased the occurrence of atrial fibrillation and predominated the sympathetic nervous system activation effects.
  • Local parasympathetic neurotransmitters infusion significantly increased the conversion of sustained atrial flutter to non sustained atrial fibrillation, and then to sinus rhythm.
  • the local parasympathetic neurotransmitters infusion significantly reversed the effects of sotalol, a class 3 antiarrhythmic drug, on the reentry circuit characteristics during a sustained atrial flutter.
  • This invention determined the significant effects of parasympathetic nervous system activation on the occurrence of atrial re-entrant arrhythmias.
  • this invention illustrated the necessity of local ablation method of the atrial areas with the greatest density of parasympathetic innervation for the treatment of atrial arrhythmias, such as the areas near the sinoatrial nodal fat pad and septal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters/blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.

Description

FIELD OF THE INVENTION
Cardiac rhythm disturbances are a major cause of morbidity and even mortality in our ageing population. Most of these rhythms are based on reentry, i.e. the continuous circulation of a wavefront of excitation around a functional or anatomical circuit such atrial fibrillation and flutter. Atrial fibrillation could exist as a stable state, self-sustained and independent of its initiating trigger in the presence of non-uniform distribution (i.e. dispersion) of atrial refractory periods. In addition, maintenance of atrial fibrillation may require a critically short wavelength in order to sustain reentry. However, the cellular and pathophysiological mechanisms in the initiation and maintenance of atrial fibrillation remain poorly understood. It has been reported that inducibility and maintenance of this atrial arrhythmia are associated with an increased dispersion in atrial refractoriness. In addition, alterations in the electrophysiologic properties of the atria affecting wavelength may led to persistence of atrial fibrillation and to the occurrence of reentrant atrial arrhythmias in both in vitro and in vivo models. Furthermore, electrical remodeling of the atria may also increase the likelihood to the maintenance of this atrial arrhythmia.
Electrophysiological studies suggest that the mechanism of type I atrial flutter in humans and in canine models involves a macroreentrant circuit around an anatomically or anisotropically defined obstacle with either a partially or fully excitable gap. The excitable gap is one of the determinant of the continued circulation of the abnormal atrial impulse and in its presence an extrastimulus may excite the circuit and reset the tachycardia. Furthermore, the persistent circulation of this wavefront is determined by the effective refractory period, the conduction velocity, the wavefront and the nature and duration of the excitable gap, i.e. that portion of the circuit which has partially or fully recovered its excitability. This excitable gap, in part, determined by the size of the reentry circuit and the electrophysiological properties of its tissue components.
However, external influences may also significantly modify the susceptibility for the occurrence of atrial arrhythmias via different electrophysiological mechanisms such as the excitable gap characteristics, the effective refractory period duration and dispersion, the conduction velocity, the wavefront duration and propagation forms and the number of the wavelets. Autonomic nervous system tone may implicitly have a role in the pathogenesis of initiation and persistence of supraventricular arrhythmias. In experimental models, both vagal stimulation and acetylcholine application to the heart can nonhomogeneously shorten atrial refractory period and produce either paroxysmal atrial arrhythmia, flutter or fibrillation. In man, the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night which correlates with an immediately preceding increase in vagal drive. Catecholamine administration (Isoproterenol) also shortens the atrial action potential and stimulation of sympathetic nerves shortens atrial refractoriness and increases its dispersion facilitating the induction of atrial fibrillation. In man, attacks of atrial fibrillation have also been reported to be associated with adrenergic activation. Little is known, however, on the possible influence of autonomic nervous system tone on an established stable reentry circuit such as is seen in atrial flutter, an arrhythmia which is frequently difficult to interrupt by pharmacological means, and also on the occurrence of the leading circle phenomena during atrial fibrillation episodes. In a human study of parasympathetic and sympathetic blockade, observations limited to effects on atrial flutter cycle length did not detect any change either in the supine or upright position. No study has yet addressed the effects of autonomic neurotransmitters on the refractory period, duration and composition of the excitable gap and thus, on the viability of an atrial reentry circuit.
Despite considerable advances in our understanding on the mechanism of this atrial arrhythmia, antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems. These drugs are either incompletely effective, may have proarrhythmic properties, and also may increase mortality. Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties, there has been increased interest in class III drugs, which act by increasing action potential duration and refractoriness without blocking sodium channels. The pharmacological control of cardiac arrhythmias using class III antiarrhythmic drugs which prolong the cardiac action potential has gained interest recently, particularly in view of reports of proarrhythmic and increased mortality associated with the use of class I antiarrhythmic drugs in the treatment of both ventricular and atrial arrhythmias. In addition, there is evidence that drugs with class III antiarrhythmic action may be more effective than the class I antiarrhythmic drugs for conversion and suppression of some cardiac arrhythmias, particularly those due to reentry. This greater efficacy of the class III antiarrhythmic drugs may be due in part to their ability to selectively prolong refractoriness and wavelength and reduce dispersion of refractoriness. Despite extensive investigation in the past, the critical electrophysiologic determinants of antiarrhythmic drug efficacy in specific reentrant tachycardias are not fully delineated. Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms. Both isomers have equal class III activity but only the l-isomer possesses significant β-adrenoceptor blocking activity. d,l-Sotalol, the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current (Iks and Ikr) and thus increases the atrial action potential duration and the atrial effective refractory period. At high concentrations, Sotalol can also inhibit the background or inward rectifying K+ (Ikl) and decreases the transient outward K+ current (Ito). Administration of class III antiarrhythmic drugs has been reported to prevent and/or terminate atrial flutter and fibrillation, an effect correlated with a shortening of the excitable gap and with prolongation of both the atrial arrhythmias cycle length and the refractory period.
The purpose of this invention is to determine the effects of norepinephrine and acetylcholine on the excitable gap composition during a sustained stable atrial flutter, and on the atrial effective refractory period duration and dispersion, atrial conduction velocity and atrial wavelength. Furthermore, this invention illustrates also the influence of autonomic nervous system activation and neurotransmitters infusion on the occurrence of these atrial arrhythmias, and whether these significant effects could alter those of sotalol on the same electrophysiological parameters. This invention also project the possibility for new atrial targets for the use of catheter ablation during the treatment of atrial arrhythmias. These new targets for catheter ablation during an atrial arrhythmia may be the fully excitable tissue, and/or the areas with the greatest density of parasympathetic innervation such as the tissues near the sinoatrial nodal fat pad and septal.
BRIEF SUMMARY OF THE INVENTION
Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced, activated and aggravated by autonomic nervous system tone. Furthermore, the treatment of this atrial arrhythmias are influenced, threaded and degenerated to a proarrhythmic events under the dominant effects of the autonomic nervous system activation. This invention evaluated the significance of sympathetic and parasympathetic activation by determining the effects of norepinephrine and acetylcholine on the composition of the excitable gap during a stable sustained atrial flutter, on the effective refractory period, on the conduction velocity, and on the wavelength in a canine model of stable atrial flutter. We also evaluated whether norepinephrine and acetylcholine administration can alter class III antiarrhythmic drug effects in the occurrence of atrial arrhythmias. This invention also evaluated the significance of sympathetic and parasympathetic denervation and activation by determining the direct effects of right and left stellar ganglions (10 Hz, 2 ms) and right vagal (1 Hz, 0.1 ms) stimulation on the atrial effective refractory period duration and dispersion, on the atrial conduction velocity, on the atrial wavelength and on the viability of the occurrence of atrial fibrillation. This invention also evaluated whether the autonomic nervous stimulation can alter class III antiarrhythmic drug (sotalol) effects in the same electrophysiological parameters described above and on the occurrence of these atrial arrhythmias.
In a group of 13 open chest anaesthetised dogs, atrial flutter model was produced during baseline conditions around the tricuspid valve using a Y-shaped lesion in the intercaval area extending to the right atrial appendage. Atrial flutter was induced at the shortest effective refractory period site using fast pacing stimulation (S1S1) of 100-150 ms. This manoeuvre was repeated as much as necessary with more damage in the Y-shaped lesion model to achieve a sustained stable atrial flutter (>10 min) during the baseline conditions. In order to determine the excitable gap duration and composition during this sustained and stable atrial flutter, a diastole was scanned with a single premature extrastimulus, S1S2 (S1S2=]refractory period, flutter cycle length[) to define the atrial flutter circuit composition and duration (flutter cycle length=refractory period+excitable gap). Atrial flutter cycle length, atrial effective refractory period and duration of the excitable gap were then determined. Measures were repeated during a constant infusion into the right coronary artery of norepinephrine (15 μg/min) and acetylcholine (2 μg/min) allowing 15 min for recovery from norepinephrine effects. The effects of norepinephrine and acetylcholine at a constant plasma level of d-sotalol or d,l-sotalol (0.8 mg/kg+0.4 mg/kg/hr) were also studied in 2 different groups of chloralose anaesthetised dogs on the same electrophysiological parameters described above.
In a group of 14 anaesthetised open chest dogs, atrial fibrillation was induced by fast pacing and up to 10 attempts of arrhythmia initiations during baseline condition, vagal denervation, right and left vagal stimulation #1 (1 Hz, 0.1 ms), right and left stellar ganglions denervation, right and left vagal stimulation #2 (1 Hz, 0.1 ms), right and left stellar ganglions stimulation (10 Hz, 2 ms), and right and left vagal stimulation (1 Hz, 0.1 ms) associated with right and left stellar ganglions stimulation (10 Hz, 2 ms). Under the same conditions described above, the effective refractory period duration and dispersion (at S1S1=200 ms), the conduction velocity and the wavelength are determined. Atrial fibrillation occurrence was evaluated by the mean duration of 10 atrial fibrillation episodes at baseline (for a group of animals when none of the 10 atrial fibrillation episodes at baseline were lasting more than 3 minutes) and following each of the conditions described above.
In summary, both neurotransmitters infusions (acetylcholine>>norepinephrine) significantly increased the occurrence of the initiation of atrial flutter and decreased the duration of its maintenance by rapid (less than 2 minutes) conversion to a non sustained atrial fibrillation and then to a sinus rhythm state. Both neurotransmitters significantly increased the safety margin of excitability ahead of the wavefront and decreased the effective refractory. Autonomic and, in particular, vagal effects significantly diminish the action of pure class III antiarrhythmic drug, d-sotalol. However, in the presence of d,l-sotalol, a class III combined with anti-adrenergic effects, only acetylcholine still completely reversed its electrophysiological effects. This suggests that class III antiarrhythmic drugs with class II properties could resist the effects of sympathetic but not that of vagal activation. The effects of autonomic nervous system stimulation also significantly increased the occurrence of atrial fibrillation initiation and persistence. The effects of vagus activation significantly exceed those of sympathetic on the occurrence of atrial fibrillation, on the atrial effective refractory period duration and dispersion, on the conduction velocity and on the wavelength. In a particular interest, when the stellar ganglions denervation facilitates the occurrence of the initiation of a non sustained atrial fibrillation following the premature stimulation (S1S2) (data described the relation between initiation vs. duration of atrial fibrillation are not presented in this invention), the vagal denervation significantly reduced its initiation and maintenance. Furthermore, in the presence of class III drug therapy, the vagal stimulation significantly and markedly reversed the antiarrhythmic therapeutic effects of d,l-sotalol. These results demonstrate an absolute and emergent need to consider the effects of the presence and of the activation of parasympathetic nervous system tone during the pharmacological treatment of atrial arrhythmias. In addition, this invention targets the areas with the greatest density of parasympathetic innervation for ablation, such as the areas located near the sinoatrial nodal fat pad and septal, for the treatment of atrial arrhythmias during a catheter ablation manner.
DETAILED DESCRIPTION OF THE INVENTION
The main purpose of this invention was to study the significant effects of autonomic nervous system on the atrial electrophysiologic parameters related to the pre-conditioning, initiation, persistence and termination of atrial fibrillation and flutter. Furthermore, this invention evaluated whether the significant effects of autonomic nervous system on the atrial electrophysiological parameters and on the occurrence of atrial arrhythmias could change those of class III antiarrhythmic drugs.
Autonomic Nervous System Effects on Atrial Tissue
The effects of sympathetic neural activity on the heart are gradually developed and receded, whereas the inhibitory effects of vagal activity appear and disappear rapidly. The automatic cells in the heart respond promptly to vagal stimulation within a steady-state value of two cardiac cycles. The ability of the vagus nerves to regulate heart rate beat by beat could be explained by the speed at which the neural signal is rapidly transduced to a cardiac response and by also by the rapidity of the processes that restore the basal heart rate when vagal activity ceases. The mechanisms of this rapid development of vagal effects on heart rate will be related to: 1) the acetylcholine regulated potassium channels; 2) the hyperpolarization activated channels, which conduct the If current; and 3) the calcium channels. The acetylcholine and the If channels could both respond rapidly to vagal activity. The If and Ica channels are directly involved in generating the slow diastolic depolarisation in sinus node cells. The release of acetylcholine interacts with cardiac muscarinic receptors that are coupled to its regulated potassium channels directly through G proteins without an interaction of a slow second messenger system. These potassium channels are fully activated by this release of acetylcholine within a few milliseconds. The relatively slow development of the sympathetic responses has been attributed mainly to the inclusion of a second messenger system, notably the adenylyl cyclase system, in the cascade of events that transduce the neuronal release of norepinephrine into a change in cardiac performance. The chronotropic response of the heart to sympathetic activation is mediated mainly via several types of ion channels, such as Ica and If currents. This second messenger system is too slow to permit beat-by-beat regulation of cardiac function. The norepinephrine released from the sympathetic nerve endings is removed from the cardiac tissues much more slowly than is the acetylcholine that is released from the vagal terminals. Then, the atrial tissue and the related ionic currents (Ica, If) are submitted to the sympathetic neural activity after a certain delay of ganglion stellar stimulation. Furthermore, during the study of vagal-sympathetic interaction, the on-set effects of sympathetic stimulation are considered in the presence of existing vagal stimulation effects on atrial tissue and not in the on-set of this vagal stimulation effects.
Autonomic Nervous System Effects in Atrial Arrhythmias
Recently, it has become increasingly recognised that beyond an understanding of the electrophysiological behaviour of an isolated reentry circuit, it is necessary also to be aware of possible external influences on the atrial arrhythmias occurrence and on the related atrial electrophysiological parameters such as the effective refractory period duration and dispersion, the conduction velocity, the wavelength and the excitable tissue during these atrial arrhythmias. Variations of autonomic tone have been hypothesised to have a role in the pathogenesis of supraventricular arrhythmia. For example, it has long been known that vagal stimulation or acetylcholine application to the heart can produce either atrial flutter or fibrillation, and can nonuniformly shorten atrial refractoriness periods, thus increasing the regional differences in atrial refractory period. In man, the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night. Further, spectral analysis of heart rate variability has suggested an increase in vagal drive immediately preceding the onset of atrial arrhythmia. Sympathetic stimulation or administration of catecholamines can also influence atrial electrophysiological properties. Isoproterenol shortens the atrial action potential and stimulation of sympathetic nerves shortens slightly atrial refractory period and can facilitate induction of atrial fibrillation. Furthermore, in man, attacks of atrial fibrillation have stellar ganglions produces localised shortening of the refractory period, increases the dispersion of refractoriness and increases the vulnerability to re-entrant arrhythmias.
The majority of the above observations have, however, been made with respect to atrial fibrillation and not atrial flutter. Indeed, very little is known of the influence of the autonomic nervous system tone on the electrophysiological characteristics of tissue within the circuit. In the only human study of autonomic system effects on atrial flutter, parasympathetic and sympathetic blockade with intravenous atropine and propranolol did not change atrial flutter cycle length either in the supine or upright position. Many of these patients were however on Class IA antiarrhythmics which in themselves have an anticholinergic effect. Furthermore, observations limited to cycle length although useful, do not describe the complex effects of the autonomic nervous system on the electrophysiological properties of tissue participating in the circuit. Only a study of the duration of the excitable gap can elucidate how the viability of the flutter circuit is modulated by autonomic effects. Indeed, properties such as atrial refractoriness and conduction velocity are influenced by autonomic input can be determined to measure the influence of autonomic nervous system on atrial arrhythmias.
Either adrenergic or vagal stimulation can favor the onset of atrial fibrillation through complex mechanisms of shortening of the atrial refractory period, affecting the heterogeneity of refractoriness, the conduction time and the resultant wavelength of the propagate of this atrial arrhythmias. Atrial fibrillation starts with a period of rapid ectopic activity that may be caused by discharge of an autonomic focus, or afterpotentials, particularly in the setting of an enhanced catecholamine state. Vagal tone stimulation initiates atrial fibrillation by hyperpolarization in the atrial tissues and fibres, an effect that does not favor either delayed afterdepolarization or pacemaker activity. Thus, it may facilitate the conditions for the reentry initiation because the duration of the P waves may actually become shorter than the time required to excite the whole atria. However, for those factors may also be the conditions for the perpetuation or the termination of those re-entrant atrial arrhythmnias. Clinical paroxysmal atrial arrhythmias suggesting a predominant vagal mechanism often display a pattern of atrial fibrillation with alternates of atrial flutter. In contrast, atrial fibrillation dependent of adrenergic activity is most likely related to ectopic automatic foci explained by their ECG appearance. The onset of atrial fibrillation that occurs in the setting of rest or digestive periods, and is preceded by a progressive heart rate decrease, could be related to a vagal activation mechanism. However, palpitations starting at exercise or stress are related to adrenergic mediation.
Class III Antiarrhythmic Drugs Mechanisms in Atrial Arrhythmias
Electrophysiological studies suggest that the mechanism of type I atrial flutter in humans and in canine models involves a macroreentrant circuit around an anatomically or anisotropically defined obstacle with either a partially or fully excitable gap. The excitable gap is one of the principle determinant of the continued circulation of the abnormal atrial impulse and in its presence an extrastimulus can preexcite the circuit and reset the tachycardia. Atrial fibrillation, a reentrant arrhythmia, is more likely to occur in the presence of an abnormally shortened atrial effective refractory period and increased dispersion of the effective refractory period. In addition, abnormally depressed conduction velocity and anatomic obstacles may play a role in the reentrant mechanism of atrial fibrillation. Experimental studies have suggested that prolongation of atrial wavelength and a reduction in effective refractory dispersion may be critical determinants of the efficacy of antiarrhythmic drugs in terminating and suppressing reentrant atrial arrhythmias. Both of these salutary electrophysiological effects are produced by class III antiarrhythmic drugs, such as sotalol. Despite their favourable electrophysiological profile, however, the class III drugs are not more effective than the class I drugs in suppressing atrial fibrillation in humans, with only 50% to 65% of patients in sinus rhythm after 6 months of therapy. In addition, the organ toxicity and potential life-threatening ventricular proarrhythmia associated with antiarrhythmic drugs further limit their use for treating atrial fibrillation. Because of the limited efficacy and potential adverse effects of antiarrhythmic drugs that modulate cardiac ion channels, new approaches to antiarrhythmic drug therapy must be developed. One possible approach is the modulation of membrane receptors that play a role in controlling normal cellular electrophysiology. Despite considerable advances in our understanding on the mechanism of this atrial arrhythmia, antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems. These drugs are either incompletely effective, may have proarrhythmic properties, and also may increase mortality. Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties, there has been increased interest in class III drugs, which act by increasing action potential duration and refractoriness without blocking sodium channels. Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms. Both isomers have equal class III activity but only the l-isomer possesses significant β-adrenoceptor blocking activity. d,l-Sotalol, the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current (Iks and Ikr) and thus increases the atrial action potential duration and the atrial effective refractory period. At high concentrations sotalol can also inhibit the background or inward rectifying K+ (Ikl) and decreases the transient outward K+ current (Ito). Administration of class III antiarrhythmic drugs has been reported to prevent and/or terminate atrial flutter an effect correlated with a shortening of the excitable gap and with prolongation of both the atrial flutter cycle length and the refractory period.
In a recent study in common human atrial flutter, edrophonium which blocks acetylcholinesterase activity had no significant effect on monophasic atrial action potential duration or atrial flutter cycle length. However, this study had some limitations. For example, the atrial monophasic action potentials were not obtained directly from the atrial flutter circuit. Furthermore, cholinesterase inhibition would not necessarily produce any change in action potential duration in the absence of simultaneous vagal activity. This invention also presents some limitations in the part of neurotransmitters infusion during the sustained atrial flutter: First, neurotransmitter infusion does not necessarily reproduce the synaptic cleft concentrations which occur with autonomic nervous system stimulation. Second, autonomic fibers may be non homogeneously distributed in the atrium and this distribution is different for the vagal and sympathetic systems. The latency time and duration of the physiological response are also different. This may contribute to a discrepancy between the effects of neurotransmitter infusion, which may produce a more homogeneous effect compared to the non homogeneous autonomic fiber stimulation. Finally, at the level of the neuroeffector junction and beyond, the effects of neurotransmitter infusion may differ from the effects of autonomic fiber stimulation. Parasympathetic and sympathetic system stimulation interact in four ways: (1) vagal stimulation inhibits the release of norepinephrine at sympathetic nerve terminals; (2) sympathetic stimulation releases neuropeptide Y, which in turn interferes with the actions of vagal stimulation, possibly by inhibiting the release of acetylcholine; (3) α-adrenergic stimulation with phenylephrine attenuates the bradycardia induced by direct vagus nerve stimulation; and (4) acetylcholine antagonizes the intracellular production of cyclic AMP by catecholamines. Therefore, the effects we observe with infusion of acetylcholine and norepinephrine likely do not reproduce quantitatively the effects of autonomic nerve activity. Nevertheless, these qualitative effects demonstrate an important modulation of atrial flutter excitable gap which can be clinically significant.
Methods
Atrial Flutter protocol: All experiments described were in accordance with institutional guidelines for animal experimentation. Fourteen mongrel dogs of either sex, weight 29-45 kg, were studied in the post-absorptive state. General anaesthesia was induced with sodium thiopental (25 mg/kg iv.) and maintained with chloralose (80 mg/kg iv. bolus supplemented by 20 mg/kg/hr maximum as needed). The dogs were intubated and ventilated (Harvard pump) with room air (10 breaths/min, tidal volume to achieve a maximum inspiratory pressure of 20 cm water) to maintain arterial pH 7.35-7.45 and PaO2>80 mm Hg. Arterial and venous cannulae were inserted in the left femoral artery and vein by direct cut down for blood pressure monitoring and drug administration, respectively. An additional venous cannulae was inserted in the right femoral vein or in the right internal jugular vein for blood sampling. Muscular relaxation was then induced with gallamine triethiodide (Flaxedil 100) 3 mg/kg intravenously. A right thoracotomy was performed via the fourth or fifth intercostal space and the pericardium was incised to provide access to the vena cava and the right atrium. According to the procedure described by Frame et al., (1986) the tissue on a line extending from the superior to the inferior venae cavae was clamped, incised and sewn over. A second line, extending from the first two-thirds of the way toward the tip of the right atrial appendage and parallel to 1-2 cm above the atrioventricular groove, was similarly incised and sewn over. Five close (2-4 mm) bipolar epicardial silver electrodes (insulated except at the tip) for stimulating and/or recording were sewn around the base of the right atrium within 1 cm of the tricuspid annulus. Three were positioned on the anterior surface and two on the posterior surface (Derakhchan K, et al., 1994). An arterial cannula was inserted in the right coronary artery for neurotransmitter infusion.
Measurement of electrophysiologic parameters: A single lead (II) surface electrocardiogram, atrial electrograms from each of the 5 bipolar electrodes, and the femoral arterial pressure were monitored and recorded using a Nihon Kohden polygraph (Model RM6008). Data were also stored on a Hewlett-Packard tape recorder. Atrial flutter was induced by burst stimulation (20-30 beats at basic cycle length <100 ms). During stable flutter (cycle length variation <10 ms), a premature stimulus was introduced at the site located on this re-entry circuit after every 20th spontaneous beat (T) in 2 ms decrements beginning at coupling intervals equal to the cycle length of this atrial tachycardia. The interval between the last spontaneous beat and the response to the subsequent premature stimulus (Coupling Interval) as well as the interval between the response to the premature stimulus and the subscript (T1) tachycardia beat (Return Cycle) were measured (peak-to-peak) at the electrode distal to the stimulating site (in the direction of wavefront propagation). Measurements were made at a paper speed of 100 mm/s using a Digimatic Caliper (Mitutoyo Corporation, Tokyo) which has a resolution of 0.01 mm. Graphs describing the relationship between the Return Cycle (ordinate) and the Coupling Interval (abscissa) of the premature beat or reset-response curves were constructed using points where (T-T1)<2 (T-T) by more than 3 ms. The refractoriness duration of this re-entry circuit was defined as the shortest coupling interval which reset this tachycardia. This excitable gap is calculated from the tissue which conducted the premature beat. The excitable gap tissue was thus the interval between the refractoriness and the total cycle length of this atrial arrhythmia. A line was fitted to the ascending portion of the reset-response curve, using all points where the Return Cycle>flutter cycle length. The duration of the flat portion was then taken from the intersection of this line with a horizontal line drawn at the flutter cycle length on the ordinate. The excitable gap was characterized by the reset-response technique as previously described by Derakhchan et al. (1994). It assumes that the reentry circuit is located in the muscle ring immediately above the tricuspid valve as has been previously demonstrated (Frame et al., 1986) and that its location in the presence of drug is unchanged. Measures were performed under control conditions before and then during a constant infusion of norepinephrine into the right coronary artery (15 μg/min) and again during an acetylcholine infusion (2 μg/min) into the same artery after allowing 15 minutes for recovery from norepinephrine effects. Completion of the entire protocol on drug usually required one hour.
Statistical analysis: Data are presented as mean±standard deviation of the mean. When multiple measurements were performed in the same population, statistical comparisons were done using one way repeated-measures ANOVA with Bonferroni's correction for pairwise multiple comparisons. For all tests, a value of P<0.05 was considered to be statistically significant (details of statistics of each parameter are presented with the in the section: Description of Tables). Linear regression as described in Methods was determined to characterise the increasing portion of the reset-response curve.
Atrial Fibrillation protocol: Fourteen mongrel dogs weighing 19-30 kg were anaesthetised with morphine (2 mg/kg i.m.) and α-chloralose (100 mg/kg iv.) and ventilated by a respirator (NSH 34RH, Harvard Apparatus, South Natick, Mass.) via an endotracheal tube at a rate of 20-25 breaths per minute with a tidal volume obtained from a nomogram. Arterial blood gases were measured to ensure adequate oxygenation (SaO2>90%) and physiological pH (7.38-7.45). Body temperature was maintained with a homiothermic heating blanket. Catheters were inserted into the left femoral artery and both femoral veins and kept patent with heparinized saline solution (0.9%). A median sternotomy was performed, an incision was made into the pericardium extending from the cranial reflection to the ventricular apex, and a pericardial cradle was created. A pair of Teflon-coated stainless steel bipolar hook electrodes, one for stimulation and the other for recording atrial electrograms, were inserted intramural into the tip of the right atrial appendage. The position of the stimulating electrodes were located in the right atrial appendage (RA-1), left atrial appendage (LA-2), inferior vena cava (IVC-3), medial vena cava (MVC-4) and superior vena cava (SVC-5). A programmable stimulator and a stimulus isolator (Bloom Assoc., Flying Hills, Pa.) were used to deliver 4-msec square-wave pulses. Operational amplifiers (Bloom Association) and a Mingograp T-16, 16 channel recorder (Siemens-Elema Ltd., Toronto, Canada) were used to record the six standard surface electrocardiogram leads, arterial pressure, and stimulus artifacts. Electrocardiographic recordings were obtained at a paper speed of 200 mm/sec.
Activation Mapping: Five thin plastic sheets containing 112 bipolar electrodes with 1 mm interpolar and 6 mm interelectrode distances were sewn into position on atrial epicardial surface. One sheet was placed under the root of aorta to cover the anterior aspect of the atrial appendages and Bachman's bundle. Three sheets were sewn to the posterior aspects of the atrial appendages and to the free walls. The parietal pericardium was gently separated, and a fifth plaque was placed between the pulmonary arteries and veins. Each signal was filtered (30 to 400 Hz), digitized with 12-bit resolution and 1-KHz sampling rate, and transmitted into a microcomputer (model 286, Compaq Computer, Houston, Tex.). Software routines were used to amplify, display, and analyse each electrogram signal as well as to generate activation maps. Each electrogram was analyzed with computer-determined peak-amplitude criteria and was reviewed manually. The accuracy of activation time measurements was±0.5 ms. The data were downloaded on high-density diskettes for subsequent off-line analysis. Isochrone maps and activation times for each activation were recorded by the use of IBM ink jet printer. Hardware and software for the mapping system were obtained from Bio-medical Instrumentation, Inc., Markham, Ontario.
Autonomic Nervous System model: Both cervical vagal trunks were isolated and decentralised approximately 3 cm proximal to the bifurcation of the common carotid artery, and bipolar hook electrodes (stainless steel insulated with Teflon except for the terminal 1-2 cm) were inserted via a 21-gauge needle into the middle of each nerve, with the electrode running within and parallel to vagal fibers for several centimetres. Both right and left stellar ganglions were found between the 2-3 intercostal level, and isolated and decentralised, then a bipolar hook electrodes were inserted via a 21-gauge needle into the dorsal and ventral ansae of each stellar ganglion. The left and right stellar ansae were stimulated with square-wave pulses of 2 ms duration, 10 Hz frequency and 6 volts. Adequate stellar stimulation was verified by an increase in arterial systolic/diastolic pressure (from the left side) and in heart rate (from the right side). Bilateral vagal nerve stimulation was delivered by an SD-9F stimulator (Grass Instruments, Inc., Quincy, Mass.), with a pulse width of 0.1 msec and a frequency of 1 Hz, with an amplitude of stimulation of 3-10 V, adjusted in each dog to two thirds of the threshold for the production of asystole under control conditions. At a constant basic cycle length of 200 ms, we have determined the effective refractory period duration and the conduction velocity at baseline, vagal and sympathetic denervation. Fifteen seconds after the initiation of vagal (1 Hz, 0.1 ms) and sympathetic stimulation (10 Hz, 2 ms), we started to determine the effective refractory period and conduction velocity duration. Atrial fibrillation initiations were determined by short burst (1-3 seconds) of atrial pacing at a cycle length of 60-100 ms and with a current amplitude of four times the diastolic threshold for atrial capture. Atrial fibrillation duration was determined by the mean of 10 atrial fibrillation episodes during baseline conditions, vagal denervation, vagal stimulation (1 Hz, 0.1 ms) during 3 minutes, sympathetic denervation, vagal stimulation (1 Hz, 0.1 ms) during 3 minutes, and on the combined vagal (1 Hz, 0.1 ms) and sympathetic (10 Hz, 2 ms) stimulation during 3 minutes. If the duration of any atrial fibrillation episode on vagal or sympathetic stimulation was >3 minutes, no further stimulation are required. Animals with atrial fibrillation duration episodes >3 minutes at baseline conditions are excluded from this study.
Results
Reversal of d-sotalol effects on the atrial flutter circuit compositions by autonomic nervous system neurotransmitters:
The characteristics of the atrial flutter circuit are detailed in Table 1 from 6 animals. Both norepinephrine and acetylcholine infusion significantly shortened the effective refractory period duration. However, only acetylcholine infusion significantly shortened the atrial flutter cycle length and the excitable gap duration. In the presence of pure class 3 antiarrhythmic drug, d-sotalol, both norepinephrine and acetylcholine significantly reversed the effects of d-sotalol on the atrial flutter cycle length and on the effective refractory period duration, but only acetylcholine infusion significantly reversed d-sotalol effects on the excitable gap duration.
Selective reversal of d,l-sotalol effects on the atrial flutter circuit compositions by the parasympathetic nervous system neurotransmitters:
The characteristics of the atrial flutter circuit are detailed in Table 2 from 7 animals. Acetylcholine infusion significantly decreased the effective refractory period duration and increased the excitable gap duration. In the presence of d,l-sotalol, a class 3 combined with anti-adrenergic effects, acetylcholine significantly reversed d,l-sotalol effects on the atrial flutter cycle length, on the effective refractory period and on the excitable gap duration.
Effects of autonomic nervous system on the atrial refractory period duration and dispersion, on the atrial conduction velocity and wavelength, and on the occurrence of atrial fibrillation after its initiation:
The results on the atrial fibrillation are detailed in Table 3 from 14 animals. Vagal denervation effects compared to the baseline conditions, significantly decreased the atrial as fibrillation duration, the effective refractory period dispersion and the conduction velocity, and significantly increased the effective refractory period duration. Sympathetic denervation did not significantly changed the effects produced by the vagal denervation. However, sympathetic stimulation significantly reversed the effects of autonomic denervation on the atrial effective refractory period duration. In contrast, vagal stimulation before and after sympathetic denervation significantly reversed the effects of autonomic denervation on the atrial fibrillation duration, on the effective refractory period duration and dispersion and on the conduction velocity. Vagal stimulation effects compared from baseline conditions, significantly increased the atrial fibrillation duration and the conduction velocity, and significantly decreased the effective refractory period duration. The combined effects of sympathetic-parasympathetic stimulation compared to those of parasympathetic stimulation alone were significantly different only on the conduction velocity, however, these combined effects compared to those of sympathetic stimulation alone are significantly different on the effective refractory period duration and dispersion and on the conduction velocity.
DESCRIPTION OF TABLES AND STATISTICS:
Table 1
Reversal of d-sotalol Effects on the Atrial Flutter Circuit Compositions by Autonomic Nervous System Neurotransmitters
Statistical analysis for atrial flutter cycle length (AFICL), effective refractory period duration (ERPdur) and excitable gap duration (EGdur) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. Data for d-sotalol are not shown in this invention.
d − S d − S
Baseline NE ACh + NE + ACh
AF1CL 132 ± 14 133 ± 12 123 ± 15*† 131 ± 8† 122 ± 9*†
ERPdur 105 ± 9    86 ± 9*† 65 ± 5*†  98 ± 8†  78 ± 8*†
EGdur  26 ± 10  44 ± 4†  48 ± 16*†   30 ± 13  44 ± 12†
Values are expressed as Mean ± SD (ms) from 6 animals.
*P < 0.05, significant difference from Baseline
†P < 0.05, significant difference from d-sotalol
Abbreviations: ACh: Acetylcholine, AF1CL: Atrial Flutter Cycle Length, d-S: d-Sotalol; EGdur: Excitable Gap duration, ERPdur: Effective Refractory Period duration, NE: Norepinephrine.

Table 2
Selective Reversal of d,l-sotalol Effects on the Atrial Flutter Circuit Compositions by Parasympathetic Neurotransmitters
Statistical analysis for atrial flutter cycle length (AF1CL), effective refractory period duration (ERPdur) and excitable gap duration (EGdur) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. Data for d,l-sotalol are not shown in this invention.
d,1 − S d,1 − S
Baseline NE ACh + NE + ACh
AF1CL 133 ± 15 132 ± 8† 119 ± 17† 144 ± 11* 126 ± 7†
AERP 105 ± 15  93 ± 7† 64 ± 4† 121 ± 13    84 ± 14
EG 27 ± 4  39 ± 3   50 ± 16*† 22 ± 12   42 ± 13*†
Values are expressed as Mean ± SD (ms) from 7 animals.
*P < 0.05, significant difference from Baseline
†P < 0.05, significant difference from d,1-sotalol
Abbreviations: ACh: Acetylcholine, AF1CL: Atrial Flutter Cycle Length, d,l-S: d-Sotalol; EGdur: Excitable Gap duration, ERPdur: Effective Refractory Period duration, NE: Norepinephrine.

Table 3
Effects of Autonomic Nervous System on Atrial Effective Refractory Period Duration and Dispersion, Atrial Conduction Velocity and Wavelength, and on the Duration of Atrial Fibrillation
Statistical analysis for atrial fibrillation duration (AFdur), effective refractory period duration (ERPdur), effective refractory period dispersion (ERPdisp), conduction velocity (CV) and wavelength (WL) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. As shown in the following statistics for each parameter, the number of animals used with each intervention are different according to the ability to realise the correct measurements.
Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 (V-S1) + (S-S10)
AFdur 34 ± 31 16 ± 19* 208 ± 21*†   8 ± 10*†α — 209 ± 29*†β  201 ± 22*†β  
ERPdur 99 ± 14 110 ± 13*   89 ± 15*† 113 ± 13*α 102 ± 11†αβ  90 ± 15*†βφ 87 ± 12*†βφ
ERPdisp 16 ± 3  11 ± 3*  19 ± 3†  13 ± 4*α 13 ± 4α   17 ± 4†βφ  17 ± 6†βφ  
CV 100 ± 16  90 ± 12* 108 ± 15*†  89 ± 10*α 95 ± 14α  111 ± 16*†βφ 115 ± 15*†αβφ
WL 10 ± 2  10 ± 1  9 ± 2  10 ± 2   10 ± 2    10 ± 2    10 ± 2   
Values are expressed as Mean ± SD from 14 animals. (n = 13 for ERPdur and ERPdisp on (V2-S1) + (S-S10) conditions; n = 12 for CV and WL; n = 7 for AFdur). ERPdur and ERPdisp are expressed in ms, CV in cm/s, WL in cm, AFdur in s. ERPdur, ERPdisp and CV are determined at a basic cycle length (S1S1) of 200 ms, AFdur are determined from the mean duration of 10 AF after its initiations.
*P < 0.05, significant difference from baseline,
†P < 0.05, significant difference vs. V-D,
αP < 0.05, significant difference vs. V1-S1,
βP < 0.05, significant difference vs. (V + S)-D,
φP < 0.05, significant difference vs. S-S10.
Abbreviations: AFdur: Atrial Fibrillation duration, Bas: Baseline conditions, CV: Conduction Velocity, ERPdur: Effective Refractory Period duration, ERPdisp: Effective Refractory Period dispersion, V-D: Vagal Denervation, V1-S1: Vagal Stimulation at 1 Hz before sympathetic denervation, (V + S)-D: Autonomic Nervous System (Vagal and Sympathetic) Denervation, S-S10: Sympathetic Stimulation at 10 Hz, V2-S1: Vagal Stimulation at 1 Hz after right and left stellar ganglions Denervation, (V-S1) + (S-S10): Vagal Stimulation at 1 Hz combined with Sympathetic Stimulation at 10 Hz, WL: Wavelength.
TABLE 1
Reversal of d-sotalol effects on the AF1CL by NE and ACh
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d-s d-S + NE d-S + ACh
1 1.0000 106.0000 118.0000 96.0000 data 122.0000 110.0000
2 2.0000 131.0000 124.0000 120.0000 data 126.0000 120.0000
3 3.0000 140.0000 144.0000 130.0000 data 128.0000 126.0000
4 4.0000 134.0000 130.0000 128.0000 data 130.0000 122.0000
5 5.0000 136.0000 132.0000 122.0000 data 134.0000 118.0000
6 7.0000 146.0000 150.0000 140.0000 data 144.0000 136.0000
7
8
9Mean 132.1667 133.0000 122.6667 data 130.6667 122.0000
10SD 13.8335 12.0499 14.8414 data 7.6594 8.6718
11SEM 5.6475 4.9193 6.0590 data 3.1269 3.5402
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.0706)
Equal Variance Test: Passed (P = 0.6738)
Group N Missing Mean Std Dev SEM
Baseline 6 0 132.2 13.83 5.65
NE 6 0 133.0 12.05 4.92
ACh 6 0 122.7 14.84 6.06
d-S 6 0 data 12.32 5.03
d-S + NE 6 0 130.7 7.66 3.13
d-S + ACh 6 0 122.0 8.67 3.54
Power of performed test with alpha = 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 5 3678.0 735.6
Between Treatments 5 1452.0 290.4 13.6 0.00000188
Residual 25 535.0 21.4
Total 35 5665.0
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.00000188). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Bonferroni's method):
Comparison Diff of Means t P < 0.05
Baseline vs d-S + ACh 10.167 3.807 Yes
Baseline vs d-S + NE 1.500 0.562 No
Baseline vs ACh 9.500 3.557 Yes
Baseline vs NE −0.833 −0.312 No
Baseline vs d-s data data —
NE vs d-S + ACh 11.000 4.119 Yes
NE vs d-S + NE 2.333 0.874 No
NE vs d-S −7.500 −2.808 No
NE vs ACh 10.333 3.869 Yes
ACh vs d-S + ACh 0.667 0.250 No
ACh vs d-S + NE −8.000 −2.995 No
ACh vs d-S −17.833 −6.677 Yes
d-S vs d-S + ACh 18.500 6.927 Yes
d-S vs d-S + NE 9.833 3.682 Yes
d-S + NE vs d-S + ACh 8.667 3.245 Yes
Reversal of d-sotalol effects on the atrial ERP by NE and ACh
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d-s d-S + NE d-S + ACh
1 1.0000 90.0000 80.0000 62.0000 data 106.0000 80.0000
2 2.0000 102.0000 78.0000 64.0000 data 100.0000 84.0000
3 3.0000 118.0000 — 58.0000 data 102.0000 64.0000
4 4.0000 106.0000 86.0000 72.0000 data 100.0000 78.0000
5 5.0000 102.0000 88.0000 68.0000 data 84.0000 82.0000
6 7.0000 110.0000 100.0000 — data — —
7
8
9Mean 104.6667 86.4000 64.8000 data 98.4000 77.6000
10SD 9.3524 8.6487 5.4037 data 8.4143 7.9246
11SEM 3.8181 3.8678 2.4166 data 3.7630 3.5440
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.2769)
Equal Variance Test: Passed (P = 0.8519)
Group N Missing Mean Std Dev SEM
Baseline 6 0 104.7 9.35 3.82
NE 6 1 86.4 8.65 3.87
ACh 6 1 64.8 5.40 2.42
d-S 6 0 data 7.16 2.92
d-S + NE 6 1 98.4 8.41 3.76
d-S + ACh 6 1 77.6 7.92 3.54
Power of performed test with alpha = 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 5 322.8 64.6
Between Treatments 5 9269.7 1853.9 29.5 0.00000000813
Residual 21 1321.0 62.9
Total 31 11735.5 378.6
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.00000000813). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 21.0
E{MS(Subj)) = var(res) + 5.20 var(Subj)
E{MS(Treatment)) var(res) + var(Treatment)
E{MS(Residual)1 var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method)
Comparison Diff of Means t P < 0.05
Baseline vs d-S + ACh 25.68 5.27 Yes
Baseline vs d-S + NE 4.88 1.00 No
Baseline vs d-S data data —
Baseline vs ACh 38.48 7.89 Yes
Baseline vs NE 18.17 3.75 Yes
NE vs d-S + ACh 7.51 1.45 No
NE vs d-S + NE −13.29 −2.58 No
NE vs d-S −31.51 −6.50 Yes
NE vs ACh 20.31 3.93 Yes
ACh vs d-S + ACh −12.80 −2.55 No
ACh vs d-S + NE −33.60 −6.70 Yes
ACh vs d-S −51.81 −10.63 Yes
d-S vs d-S + ACh 39.01 8.00 Yes
d-S vs d-S + NE 18.21 3.73 Yes
d-S + NE vs d-S + ACh 20.80 4.15 Yes
Reversal of d-sotalol effects on the atrial EG by NE and Ach
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d-s d-S + NE d-S + ACh
1 1.0000 16.0000 38.0000 34.0000 data 16.0000 30.0000
2 2.0000 29.0000 46.0000 56.0000 data 26.0000 36.0000
3 3.0000 12.0000 — 72.0000 data 26.0000 62.0000
4 4.0000 21.0000 44.0000 42.0000 data 30.0000 44.0000
5 5.0000 34.0000 44.0000 34.0000 data 50.0000 36.0000
6 7.0000 36.0000 50.0000 — data — —
7
8
9Mean 25.8333 44.4000 47.6000 data 29.6000 41.6000
10SD 9.7245 4.3359 16.3340 data 12.5220 12.4419
11SEM 3.9700 1.9391 7.3048 data 5.6000 5.5642
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.2769)
Equal Variance Test: Passed (P = 0.8519)
Group N Missing Mean Std Dev SEM
Baseline 6 0 25.8 9.72 3.97
NE 6 1 44.4 4.34 1.94
ACh 6 1 47.6 16.33 7.30
d-S 6 0 data 8.80 3.59
d-S + NE 6 1 29.6 12.52 5.60
d-S + ACh 6 1 41.6 12.44 5.56
Power of performed test with alpha = 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 5 1177.9 235.6
Between Treatments 5 3368.9 673.8 6.83 0.000631
Residual 21 2071.3 98.6
Total 31 6283.9 202.7
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.000631). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 21.0
E{MS(Subj)} = var(res) + 5.20 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method)
Comparison Diff of Means t P < 0.05
Baseline vs d-S + ACh −17.87 −2.927 No
Baseline vs d-S + NE −5.87 −0.962 No
Baseline vs d-S data data —
Baseline vs ACh −23.87 −3.855 Yes
Baseline vs NE −19.23 −3.167 No
NE vs d-S + ACh 1.35 0.210 No
NE vs d-S + NE 13.35 2.066 No
NE vs d-S 22.56 3.716 Yes
NE vs ACh −4.65 −0.719 No
ACh vs d-S + ACh 6.00 0.955 No
ACh vs d-S + NE 18.00 2.866 No
ACh vs d-S 27.21 4.456 Yes
d-S vs d-S + ACh −21.21 −3.473 Yes
d-S vs d-S + NE −9.21 −1.508 No
d-S + NE vs d-S + ACh −12.00 −1.910 No
TABLE 2
Selective reversal of d,1-sotalol effects on the AF1CL by ACh
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d,1-S d,1-S + NE d,1-S + ACh
1 1.0000 118.0000 130.0000 112.0000 data 130.0000 124.0000
2 2.0000 124.0000 — 102.0000 data 145.0000 130.0000
3 3.0000 130.0000 121.0000 126.0000 data 144.0000 120.0000
4 4.0000 114.0000 — 100.0000 data 132.0000 116.0000
5 5.0000 150.0000 — — — — 136.0000
6 6.0000 144.0000 140.0000 138.0000 data 154.0000 128.0000
7 7.0000 148.0000 136.0000 136.0000 data 158.0000 130.0000
8
9Mean 132.5714 131.7500 119.0000 data 143.8333 126.2857
10SD 14.7745  8.2614  16.7212 data 11.2857 6.7753
11SEM 5.5842  4.1307  6.8264 data 4.6074 2.5608
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.6219)
Equal Variance Test: Passed (P = 0.1191)
Group N missing Mean Std Dev SEM
Baseline 7 0 132.6 14.77 5.58
NE 7 3 131.8 8.26 4.13
ACh 7 1 119.0 16.72 6.83
d,1-S 7 1 143.0 13.19 5.39
d,1-S + NE 7 1 143.8 11.29 4.61
d,1-S + ACh 7 0 126.3 6.78 2.56
Power of performed test with alpha = 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 6 3715.4 619.2
Between Treatments 5 3080.4 616.1 15.1 0.000000965
Residual 24 979.3 40.8
Total 35 7492.6 214.1
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.000000965). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 24.0
E{MS(Subj)} = var(res) + 5.00 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method):
Comparison Diff of Means t P < 0.05
Baseline vs d,1-S + ACh 6.286 1.841 No
Baseline vs d,1-S + NE −13.524 −3.734 Yes
Baseline vs d,1-S data data —
Baseline vs ACh 11.310 3.123 No
Baseline vs NE 3.226 0.778 No
NE vs d,1-S + ACh 3.060 0.738 No
NE vs d,1-S + NE −16.750 −3.983 Yes
NE vs d,1-S −15.917 −3.785 Yes
NE vs ACh 8.083 1.922 No
ACh vs d,1-S + ACh −5.024 −1.387 No
ACh vs d,1-S + NE −24.833 −6.733 Yes
ACh vs d,1-S −24.000 −6.507 Yes
d,1-S vs d,1-S + ACh 18.976 5.240 Yes
d,1-S vs d,1-S + NE −0.833 −0.226 No
d,1-S + NE vs d,1-S + ACh 19.810 5.470 Yes
Selective reversal of d,1-sotalol effects on the atrial ERP b ACh
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d,1-s d,1-S + NE d,1-S + ACh
1 1.0000  86.0000 88.0000 58.0000 data 100.0000 74.0000
2 2.0000 100.0000 — 62.0000 data 122.0000 80.0000
3 3.0000 104.0000 86.0000 64.0000 data 114.0000 66.0000
4 4.0000  88.0000 — 64.0000 data 134.0000 88.0000
5 5.0000 120.0000 — — data — 92.0000
6 6.0000 122.0000 102.0000 — data 132.0000 108.0000
7 7.0000 114.0000 96.0000 70.0000 data 124.0000 80.0000
8
9Mean 104.8571 93.0000 63.6000 data 121.0000 84.0000
10SD  14.5537 7.3937 4.3359 data 12.5698 13.6137
11SEM  5.5008 3.6968 1.9391 data 5.1316 5.1455
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.0692)
Equal Variance Test: Passed (P = 0.8009)
Group N Missing Mean Std Dev SEM
Baseline 7 0 104.9 14.55 5.50
NE 7 3 93.0 7.39 3.70
ACh 7 2 63.6 4.34 1.94
d,1-S 7 1 data 19.12 7.84
d,1-S + NE 7 1 121.0 12.57 5.13
d,1-S + ACh 7 0 84.0 13.61 5.15
Power of performed test with alpha = 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 6 3472.2 578.7
Between Treatments 5 13459.0 2691.8 34.7 0.000000000563
Residual 23 1785.8 77.6
Total 34 19839.5 583.5
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.000000000563). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 23.0
E{MS(Subj)} = var(res) + 4.83 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method)
Comparison Diff of Means t P < 0.05
Baseline vs d,1-S + ACh 20.86 4.428 Yes
Baseline vs d,1-S + NE −18.07 −3.617 Yes
Baseline vs d,1-S data data —
Baseline vs ACh 35.70 6.738 Yes
Baseline vs NE 10.55 1.844 No
NE vs d,1-S + ACh 10.31 1.801 No
NE vs d,1-S + NE −28.62 −4.932 Yes
NE vs d,1-S −30.62 −5.277 Yes
NE vs ACh 25.15 4.112 Yes
ACh vs d,1-S + ACh −14.85 −2.802 No
ACh vs d,1-S + NE −53.78 −9.986 Yes
ACh vs d,1-S −55.78 −10.357 Yes
d,1-S vs d,1-S + ACh 40.93 8.193 Yes
d,1-S vs d,1-S + NE 2.00 0.393 No
d,1-S + NE vs d,1-S + ACh 38.93 7.792 Yes
Selective reversal of d,l-sotalol effects on the atrial EG by ACh
-1- -2- -3- -4- -5- -6- -7-
Dog# Baseline NE ACh d,1-s d,1-S + NE d,1-S + ACh
1 1.0000 32.0000 42.0000 54.0000 data 30.0000 50.0000
2 2.0000 24.0000 — 44.0000 data 23.0000 50.0000
3 3.0000 26.0000 35.0000 62.0000 data 30.0000 54.0000
4 4.0000 26.0000 — 26.0000 data 2.0000 28.0000
5 5.0000 30.0000 — — — — 44.0000
6 6.0000 22.0000 38.0000 — data 12.0000 20.0000
7 7.0000 30.0000 40.0000 66.0000 data 34.0000 50.0000
8
9Mean 25.8333 38.7500 50.4000 data 21.8333 42.2857
10SD 9.7245 2.9861 16.0250 data 12.4325 13.0348
11SEM 3.9700 1.4930 7.1666 data 5.07555 4.9267
One Way Repeated Measures Analysis of Variance
Normality Test: Failed (P = 0.0328)
Equal Variance Test: Passed (P = 0.8347)
Group N Missing Mean Std Dev SEM
Baseline 7 0 27.1 3.63 1.37
NE 7 3 38.8 2.99 1.49
ACh 7 2 50.4 16.02 7.17
d,1-S 7 1 data 16.59 6.77
d,1-S + NE 7 1 21.8 12.43 5.08
d,1-S + ACh 7 0 42.3 13.03 4.93
Power of performed test with alpha = 0.0500:0.9996
Source of Variance DF SS MS F P
Between Subjects 6 2655.8 442.6
Between Treatments 5 3733.0 746.6 10.4 0.0000253
Residual 23 1645.3 71.5
Total 34 8549.5 251.5
The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.0000253). To
isolate the group or groups that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 23.0
E{MS(Subj)} = var(res) + 4.83 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method)
Comparison Diff of Means t P < 0.05
Baseline vs d,1-S + ACh −15.14 −3.350 Yes
Baseline vs d,1-S + NE 4.93 1.028 No
Baseline vs d,1-S data data —
Baseline vs ACh −21.89 −4.305 Ycs
Baseline vs NE −8.32 −1.515 No
NE vs d,1-S + ACh −6.82 −1.242 No
NE vs d,1-S + NE 13.25 2.379 No
NE vs d,1-S 15.08 2.708 No
NE vs ACh −13.57 −2.312 No
ACh vs d,1-S + ACh 6.75 1.328 No
ACh vs d,1-S + NE 26.82 5.189 Yes
ACh vs d,1-S 28.66 5.544 Yes
d,1-S vs d,1-S + ACh −21.90 −4.568 Yes
d,1-S vs d,1-S + NE −1.83 −0.375 No
d,1-S + NE vs d,1-S + ACh −20.07 −4.186 Yes
TABLE 3
Effects of Autonomic Nervous Syst. on Atrial Fibrillation duration
-1- -2- -3- -4- -5- -6- -7- -8-
Mean-10 AF Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1Dog#1 22.0000 9.0000 204.0000 9.0000 14.0000 260.0000 194.0000
2Dog#2 33.0000 13.0000 189.0000 17.0000 13.0000 238.0000 190.0000
3Dog#5 97.0000 44.0000 238.0000 31.0000 — 230.0000 209.0000
4Dog#10 63.0000 56.0000 230.0000 36.0000 12.0000 214.0000 184.0000
5Dog#12 22.0000 9.0000 190.0000 15.0000 — 182.0000 188.0000
6Dog#13 34.0000 5.0000 189.0000 43.0000 — 208.0000 248.0000
7Dog#14 13.0000 4.0000 218.0000 9.0000 — 183.0000 194.0000
8
9
10
11
12Mean 40.5714 20.0000 208.2857 18.5714 — 216.4286 201.0000
13SD 29.5458 20.9921 20.5970 10.7060 — 28.6581 22.1736
14SEM 11.1673 7.9343 7.7849 4.0465 — 10.8317 8.3808
One Way Repeated Measures Analysis of Variance
Normality Test: Failed (P = 0.0192)
Test execution ended by user request, RM ANOVA on Ranks begun
Friedman Repeated Measures Analysis of Variance on Ranks
Group N Missing Median 25% 75%
Bas 7 0 33.00 22.00 55.8
V-D 7 0 9.00 6.00 36.3
V1-S1 7 0 204.00 189.25 227.0
(V + S)-D 7 0 15.00 10.00 27.5
V2-S1 7 0 214.00 189.25 236.0
V-S1 + S-S10 7 0 194.00 188.50 205.3
Tested 7 0
Chi-square = 30.5 with 5 degrees of freedom. (P < 0.0001)
The differences in the median values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = 0.0000116)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison procedures.(Student-Newman-Keuls Method):
Comparison Diff of Ranks p q P < 0.05
V1-S1 vs V-D 27.50 6 5.56 Yes
V1-S1 vs (V + S)-D 25.50 5 6.10 Yes
V1-S1 vs Bas 16.00 4 4.68 Yes
V1-S1 vs V-S1 + S-S10 4.00 3 1.51 No
V1-S1 vs V2-S1 2.00 2 1.07 Do Not Test
V2-S1 vs V-D 25.50 5 6.10 Yes
V2-S1 vs (V + S)-D 23.50 4 6.88 Yes
V2-S1 vs Bas 14.00 3 5.29 Yes
V2-S1 vs V-S1 + S-S10 2.00 2 1.07 Do Not Test
V-S1 + S-S10 vs V-D 23.50 4 6.88 Yes
V-S1 + S-S10 vs (V + S)-D 21.50 3 8.13 Yes
V-S1 + S-S10 vs Bas 12.00 2 6.41 Yes
Ban vs V-D 11.50 3 4.35 Yes
Bas vs (V + S)-D 9.50 2 5.08 Yes
(V + S)-D vs V-D 2.00 2 1.07 No
Effects of Autonomic Nervous Syst. on AF duration (10 initiations)
-1- -2- -3- -4- -5- -6- -7- -8-
Dog#1/Init# Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1#1 3.0000 1.0000 204.0000 3.0000 20.0000 260.0000 194.0000
2#2 2.0000 2.0000 2.0000 —
3#3 2.0000 2.0000 — —
4#4 30.0000 4.0000 10.0000 —
5#5 45.0000 — 2.0000 14.0000
6#6 80.0000 5.0000 4.0000 —
7#7 12.0000 — — 10.0000
8#8 14.0000 7.0000 14.0000 —
9#9 25.0000 46.0000 21.0000 10.0000
10#10 5.0000 2.0000 17.0000 —
11
12Mean 21.7000 8.6250 204.0000 9.1250 13.5000 260.0000 194.0000
13SD 24.9891 15.2310 0.0000 7.4917 4.7258 0.0000 0.0000
14SEM 7.9023 5.3850 0.0000 2.6487 2.3629 0.0000 0.0000
-9- -10- -11- -12- -13- -14- -15- -16-
Dog#2
1#1 45.0000 10.0000 189.0000 — 12.0000 238.0000 190.0000
2#2 9.0000 2.0000 14.0000 24.0000
3#3 14.0000 — 17.0000 20.0000
4#4 75.0000 — 2.0000 10.0000
5#5 2.0000 3.0000 4.0000 10.0000
6#6 10.0000 14.0000 — 8.0000
7#7 0.0000 21.0000 12.0000 5.0000
8#8 17.0000 40.0000 22.0000 —
9#9 5.0000 12.0000 10.0000 —
10#10 154.0000 5.0000 53.0000 —
11
12Mean 33.1000 13.3750 189.0000 16.7500 12.7143 238.0000 190.0000
13SD 48.4251 12.4664 0.0000 16.0245 6.7999 0.0000 0.0000
14SEM 15.3134 4.4075 0.0000 5.6655 2.5701 0.0000 0.0000
-17- -18- -19- -20- -21- -22- -23- -24-
Dog#5
1#1 108.0000 80.0000 238.0000 — — 230.0000 209.0000
2#2 36.0000 45.0000 24.0000 —
3#3 42.0000 65.0000 104.0000
4#4 80.0000 40.0000 23.0000 —
5#5 30.0000 — — —
6#6 104.0000 24.0000 5.0000 —
7#7 174.0000 74.0000 — —
8#8 160.0000 12.0000 10.0000 —
9#9 170.0000 — 17.0000 —
10#10 69.0000 12.0000 33.0000
11
12Mean 97.3000 44.0000 238.0000 30.8571 — 230.0000 209.0000
13SD 55.4818 26.9974 0.0000 33.5630 — 0.0000 0.0000
14SEM 17.5449 9.5450 0.0000 12.6856 — 0.0000 0.0000
25- -26- -27- -28- -29- -30- -31- -32-
Dog#10
1#1 — — 230.0000 4.0000 14.0000 214.0000 184.0000
2#2 12.0000 — 7.0000 12.0000
3#3 74.0000 18.0000 14.0000 —
4#4 24.0000 100.0000 82.0000 —
5#5 51.0000 — 90.0000 12.0000
6#6 10.0000 45.0000 23.0000 —
7#7 102.0000 — 21.0000 10.0000
8#8 80.0000 60.0000 11.0000 —
9#9 60.0000 44.0000 2.0000 —
10#10 158.0000 69.0000 105.0000 —
11
12Mean 63.4444 56.0000 230.0000 35.9000 12.0000 214.0000 184.0000
13SD 47.4845 27.6767 0.0000 39.8844 1.6330 0.0000 0.0000
14SEM 15.8282 11.2990 0.0000 12.6126 0.8165 0.0000 0.0000
-33- -34- -35- -36- -37- -38- -39- -40-
Dog#12
1#1 2.0000 1.0000 160.0000 11.0000 — 182.0000 188.0000
2#2 5.0000 20.0000 220.0000 13.0000
3#3 36.0000 3.0000 —
4#4 14.0000 8.0000 12.0000
5#5 18.0000 7.0000 11.0000
6#6 61.0000 5.0000 24.0000
7#7 23.0000 12.0000 28.0000
8#8 41.0000 23.0000 26.0000
9#9 — 5.0000 2.0000
10#10 2.0000 3.0000 5.0000
11
12Mean 22.4444 8.7000 190.0000 14.6667 — 182.0000 188.0000
13SD 20.1439 7.4394 42.4264 9.2466 — 0.0000 0.0000
14SEM 6.7146 2.3525 30.0000 3.0822 — 0.0000 0.0000
-41- -42- -43- -44- -45- -46- -47- -48-
dog#13
1#1 34.0000 1.0000 189.0000 5.0000 — 208.0000 248.0000
2#2 32.0000 2.0000 14.0000 22.0000
3#3 54.0000 4.0000 24.0000 —
4#4 87.0000 2.0000 32.0000 —
5#5 60.0000 1.0000 11.0000 —
6#6 2.0000 — 5.0000 —
7#7 45.0000 — 8.0000 —
8#8 4.0000 8.0000 12.0000 —
9#9 7.0000 14.0000 2.0000 —
10#10 11.0000 6.0000 14.0000
11
12Mean 33.6000 4.7500 189.0000 12.7000 22.0300 208.0000 248.0000
13SD 28.2654 4.4960 0.0000 9.2021 0.0000 0.0000 0.0000
14SEM 8.9383 1.5896 0.0000 2.9099 0.0000 0.0000 0.0000
-49- -50- -51- -52- -53- -54- -55- -56-
dog#13
1#1 18.0000 2.0000 218.0000 14.0000 — 183.0000 194.0000
2#2 21.0000 4.0000 28.0000 —
3#3 — 1.0000 2.0000 —
4#4 — 2.0000 — —
5#5 18.0000 4.0000 — —
6#6 14.0000 3.0000 — —
7#7 — 2.0000 3.0000 —
8#8 5.0000 5.0000 6.0000 —
9#9 10.0000 15.0000 8.0000 —
10#10 3.0000 2.0000 5.0000
11
12Mean 12.7143 4.0000 218.0000 9.4286 — 183.0000 194.0000
13SD 6.9213 4.0552 0.0000 9.0895 — 0.0000 0.0000
14SEM 2.6160 1.2824 0.0000 3.4355 — 0.0000 0.0000
Effects of Autonomic Nervous System on atrial ERP duration
-1- -2- -3- -4- -5- -6- -7- -8-
Dogs # Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1 1.0000 104.0000 118.0000 94.0000 122.0000 102.0000 100.0000 92.0000
2 2.0000 104.0000 108.0000 98.0000 112.0000 108.0000 102.0000 96.0000
3 3.0000 85.0000 93.0000 73.0000 98.0000 88.0000 78.0000 75.0000
4 4.0000 120.0000 125.0000 105.0000 120.0000 113.0000 105.0000 100.0000
5 5.0000 124.0000 130.0000 118.0000 134.0000 120.0000 120.0000 108.0000
6 6.0000 93.0000 117.0000 80.0000 130.0000 93.0000 83.0000
7 7.0000 88.0000 108.0000 78.0000 104.0000 94.0000 76.0000 76.0000
8 8.0000 90.0000 100.0000 76.0000 106.0000 94.0000 78.0000 76.0000
9 9.0000 84.0000 100.0000 76.0000 102.0000 96.0000 74.0000 76.0000
10 10.0000 110.0000 115.0000 90.0000 110.0000 110.0000 90.0000 85.0000
11 11.0000 98.0000 108.0000 86.0000 110.0000 102.0000 92.0000 82.0000
12 12.0000 104.0000 112.0000 96.0000 116.0000 108.0000 90.0000 90.0000
13 13.0000 76.0000 82.0000 66.0000 88.0000 82.0000 66.0000 70.0000
14 14.0000 112.0000 120.0000 104.0000 124.0000 114.0000 102.0000 100.0000
15
16Mean 99.4286 109.7143 88.5714 112.5714 101.7143 89.7143 86.6154
17SD 14.1895 12.8628 14.7007 12.7322 10.9715 14.8864 11.9620
18SEM 3.7923 3.4377 3.9289 3.4028 2.9323 3.9786 3.3177
One Way Repeated Measures Analysis of Variance
Normality Test: Failed (P = 0.0181)
Equal Variance Test: Passed (P = 0.8712)
Group N Missing Mean Std Dev SEM
Bas 14 0 99.4 14.2 3.79
V-D 14 0 109.7 12.9 3.44
V1-S1 14 0 88.6 14.7 3.93
(V + S)-D 14 0 112.6 12.7 3.40
S-S10 14 0 101.7 11.0 2.93
V2-S1 14 0 89.7 14.9 3.98
V-S1) + (S-S10 14 1 86.6 12.0 3.32
Power of performed test with alpha 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 13 14275.0 1098.1
Between Treatments 6 8987.0 1497.8 73.3 8.49E-030
Residual 77 1572.9 20.4
Total 96 24534.0 258.7
The differences in the mean values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = 8.49E-030). To isolate the group or groups that
differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF Residual = 77.0
E{MS(Subj)} = var(res) + 6.92 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} = var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method):
Comparison Diff of Means t P < 0.05
Bas vs V-S1) + (S-S10 12.89 7.380 Yes
Bas vs V2-S1 9.71 5.687 Yes
Bas vs S-S10 −2.29 −1.338 No
Bas vs (V + S)-D 13.14 −7.694 Yes
Bas vs V1-S1 10.86 6.356 Yes
Bas vs V-D −10.29 −6.021 Yes
V-D vs V-S1) + (S-S10 23.17 13.270 Yes
V-D vs V2-S1 20.00 11.708 Yes
V-D vs S-S10 8.00 4.683 Yes
V-D vs (V + S)-D −2.86 −1.673 No
V-D vs V1-S1 21.14 12.377 Yes
V1-S1 vs V-S1) + (S-S10 2.03 1.162 No
V1-S1 vs V2-S1 −1.14 −0.669 No
V1-S1 vs S-S10 −13.14 −7.694 Yes
V1-S1 vs (V + S)-D −24.00 −14.049 Yes
(V + S)-D vs V-S1) + (S-S10 26.03 14.907 Yes
(V + S)-D vs V2-S1 22.86 13.380 Yes
(V + S)-D vs S-S10 10.86 6.356 Yes
S-S10 vs V-S1) + (S-S10 15.17 8.689 Yes
S-S10 vs V2-S1 12.00 7.025 Yes
V2-S1 vs V-S1) + (S-S10 3.17 1.817 No
Effects of Autonomic Nervous System on atrial ERP dispersion
-1- -2- -3- -4- -5- -6- -7- -8-
Dogs # Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1 1.0000 18.0000 11.0000 19.0000 8.0000 13.0000 20.0000 28.0000
2 2.0000 21.0000 18.0000 24.0000 16.0000 16.0000 23.0000 21.0000
3 3.0000 13.0000 10.0000 17.0000 13.0000 13.0000 15.0000 19.0000
4 4.0000 18.0000 13.0000 21.0000 18.0000 15.0000 21.0000 16.0000
5 5.0000 21.0000 14.0000 16.0000 15.0000 20.0000 16.0000 16.0000
6 6.0000 21.0000 15.0000 26.0000 17.0000 21.0000 21.0000
7 7.0000 15.0000 8.0000 16.0000 11.0000 15.0000 18.0000 13.0000
8 8.0000 16.0000 10.0000 15.0000 9.0000 11.0000 11.0000 13.0000
9 9.0000 11.0000 7.0000 18.0000 15.0000 9.0000 15.0000 19.0000
10 10.0000 14.0000 7.0000 14.0000 14.0000 14.0000 14.0000 7.0000
11 11.0000 18.0000 13.0000 18.0000 7.0000 8.0000 22.0000 23.0000
12 12.0000 15.0000 11.0000 18.0000 17.0000 8.0000 16.0000 14.0000
13 13.0000 11.0000 8.0000 17.0000 8.0000 8.0000 11.0000 10.0000
14 14.0000 18.0000 12.0000 21.0000 9.0000 9.0000 18.0000 16.0000
15
16Mean 16.4286 11.2143 18.5714 12.6429 12.8571 17.2143 16.5385
17SD 3.4354 3.2148 3.3904 3.8751 4.3120 3.8666 5.5620
18SEM 0.9182 0.8592 0.9061 1.0357 1.1524 1.0334 1.5426
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.0589)
Equal Variance Test: Failed (P = 0.0181)
Mean
Group N Missing Std Dev Std Dev SEM
Bas 14 0 16.4 3.44 0.918
V-D 14 0 11.2 3.21 0.859
V1-S1 14 0 18.6 3.39 0.906
(V + S)-D 14 0 12.6 3.88 1.036
S-S10 14 0 12.9 4.31 1.152
V2-S1 14 0 17.2 3.87 1.033
V-S1) + (S-S10 14 1 16.5 5.56 1.543
Power of performed test with alpha 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 13 735.2 56.55
Between Treatments 6 666.3 111.05 12.1 0.00000000148
Residual 77 704.5 9.15
Total 96 20883 21.76
The differences in the mean values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = 0.00000000148). To isolate the group or groups
that differ from the others use a multiple comparison procedure.
Expected Mean Squares:
Approximate DF-Residual = 77.0
E{MS(Subj)} = var(res) + 6.92 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} = var(res)
All Pairwise Multiple Comparison Procedures (Bonferroni's method):
Comparison Diff of Means t P < 0.05
Bas vs V-S1) + (S-S10 −0.521 −0.446 No
Bas vs V2-S1 −0.786 −0.687 No
Bas vs S-S10 3.571 3.124 No
Bas vs (V + S)-D 3.786 3.311 Yes
Bas vs V1-S1 −2.143 −1.874 No
Bas vs V-D 5.214 4.561 Yes
V-D vs V-S1) + (S-S10 −5.735 −4.908 Yes
V-D vs V2-S1 −6.000 −5.248 Yes
V-D vs S-S10 −1.643 −1.437 No
V-D vs (V + S)-D −1.429 −1.250 No
V-D vs V1-S1 −7.357 −6.435 Yes
V1-S1 vs V-S1) + (S-S10 1.622 1.388 No
V1-S1 vs V2-S1 1.357 1.187 No
V1-S1 vs S-S10 5.714 4.998 Yes
V1-S1 vs (V + S)-D 5.929 5.186 Yes
(V + S)-D vs V-S1) + (S-S10 −4.307 −3.685 Yes
(V + S)-D vs V2-S1 −4.571 −3.998 Yes
(V + S)-D vs S-S10 −0.214 −0.187 No
S-S10 vs V-S1) + (S-S10 −4.092 −3.502 Yes
S-S10 vs V2-S1 −4.357 −3.811 Yes
V2-S1 vs V-S1) + (S-S10 0.265 0.226 No
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog1)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 130.0000 130.0000 120.0000 130.0000 120.0000 120.0000 120.0000
2LA-app 100.0000 120.0000 100.0000 130.0000 100.0000 120.0000 120.0000
3RA-IVC 110.0000 120.0000 100.0000 120.0000 110.0000 100.0000 90.0000
4RA-MVC 100.0000 120.0000 80.0000 110.0000 90.0000 80.0000 70.0000
5RA-SVC 80.0000 100.0000 70.0000 120.0000 90.0000 80.0000 60.0000
6
7Mean 104.0000 118.0000 94.0000 122.0000 102.0000 100.0000 92.0000
8SD 18.1659 10.9545 19.4936 8.3666 13.0384 20.0000 27.7489
9SEM 8.1240 4.8990 8.7178 3.7417 5.8310 8.9443 12.4097
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog2)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 120.0000 120.0000 110.0000 120.0000 120.0000 110.0000 110.0000
2LA-app 130.0000 130.0000 130.0000 130.0000 120.0000 130.0000 120.0000
3RA-IVC 100.0000 110.0000 100.0000 120.0000 120.0000 110.0000 100.0000
4RA-MVC 80.0000 90.0000 70.0000 100.0000 90.0000 70.0000 70.0000
5RA-SVC 90.0000 90.0000 80.0000 90.0000 90.0000 90.0000 80.0000
6
7Mean 104.0000 108.0000 98.0000 112.0000 108.0000 102.0000 96.0000
8SD 210.7364 17.8885 23.8747 16.4317 16.4317 22.8035 20.7364
9SEM 9.2736 8.0000 10.6771 7.3485 7.3485 10.1980 9.2736
Effective Refractory Period (ERP) dispersion (disp) (4 sites, dog3)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 100.0000 100.0000 90.0000 110.0000 100.0000 90.0000 90.0000
2LA-app
3RA-IVC 90.0000 100.0000 80.0000 100.0000 90.0000 90.0000 90.0000
4RA-MVC 80.0000 90.0000 70.0000 100.0000 90.0000 70.0000 70.0000
5RA-SVC 70.0000 80.0000 50.0000 80.0000 70.0000 60.0000 50.0000
6
7Mean 85.0000 92.5000 72.5000 97.5000 87.5000 77.5000 75.0000
8SD 12.9099 9.5743 17.0783 12.5831 12.5831 15.0000 19.1485
9SEM 6.4550 4.7871 8.5391 6.2915 6.2915 7.5000 9.5743
Effective Refractory Period (ERP) dispersion (disp) (4 sites, dog4)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1 RA-app 130.0000 130.0000 110.0000 130.0000 130.0000 110.0000 100.0000
2LA-app 140.0000 140.0000 130.0000 140.0000 120.0000 130.0000 120.0000
3RA-IVC 100.0000 110.0000 100.0000 100.0000 100.0000 100.0000 100.0000
4RA-MVC 110.0000 120.0000 80.0000 110.0000 100.0000 80.0000 80.0000
5RA-SVC
6
7Mean 120.0000 125.0000 105.0000 120.0000 112.5000 105.0000 100.0000
8SD 18.2574 12.9099 20.8167 18.2574 15.0000 20.8167 16.3299
9SEM 9.1287 6.4550 10.4083 9.1287 7.5000 10.4083 8.1650
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog5)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 140.0000 140.0000 130.0000 150.0000 140.0000 130.0000 120.0000
2LA-app 150.0000 150.0000 140.0000 150.0000 140.0000 140.0000 130.0000
3RA-IVC 120.0000 120.0000 110.0000 130.0000 120.0000 110.0000 100.0000
4RA-MVC 100.0000 120.0000 110.0000 120.0000 100.0000 120.0000 100.0000
5RA-SVC 110.0000 120.0000 100.0000 120.0000 100.0000 100.0000 90.0000
6
7Mean 124.0000 130.0000 118.0000 134.0000 120.0000 120.0000 108.0000
8SD 20.7364 14.1421 16.4317 15.1658 20.0000 15.8114 16.4317
9SEM 9.2736 6.3246 7.3485 6.7823 8.9443 7.0711 7.3485
Effective Refractory Period (ERP) dispersion (disp) (3 sites, dog6)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 110.0000 120.0000 100.0000 140.0000 110.0000 100.0000
2LA-app 100.0000 130.0000 90.0000 140.0000 100.0000 90.0000 —
3RA-IVC 70.0000 100.0000 50.0000 110.0000 70.0000 60.0000 —
4RA-MVC
5RA-SVC
6
7Mean 93.3333 116.6667 80.0000 130.0000 93.3333 83.3333 —
8SD 20.8167 15.2753 26.4575 17.3205 20.8167 20.8167 —
9SEM 12.0185 8.8192 15.2753 10.0000 12.0185 12.0185 —
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog7)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 110.0000 120.0000 100.0000 120.0000 110.0000 100.0000 90.0000
2LA-app 90.0000 110.0000 90.0000 100.0000 110.0000 90.0000 90.0000
3RA-IVC 70.0000 100.0000 60.0000 110.0000 80.0000 60.0000 70.0000
4RA-MVC 90.0000 110.0000 70.0000 100.0000 90.0000 70.0000 70.0000
5RA-SVC 80.0000 100.0000 70.0000 90.0000 80.0000 60.0000 60.0000
6
7Mean 88.0000 108.0000 78.0000 104.0000 94.0000 76.0000 76.0000
8SD 14.8324 8.3666 16.4317 11.4018 15.1658 18.1659 13.4164
9SEM 6.6332 3.7417 7.3485 5.0990 6.7823 8.1240 6.0000
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog8)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 110.0000 110.0000 100.0000 110.0000 110.0000 90.0000 90.0000
2LA-app 90.0000 100.0000 80.0000 100.0000 100.0000 90.0000 90.0000
3RA-IVC 70.0000 90.0000 60.0000 100.0000 90.0000 70.0000 60.0000
4RA-MVC 80.0000 90.0000 70.0000 100.0000 90.0000 70.0000 70.0000
5RA-SVC 100.0000 110.0000 70.0000 120.0000 80.0000 70.0000 70.0000
6
7Mean 90.0000 100.0000 76.0000 106.0000 94.0000 78.0000 76.0000
8SD 15.8114 10.0000 15.1658 8.9443 11.4018 10.9545 13.4164
9SEM 7.0711 4.4721 6.7823 4.0000 5.0990 4.8990 6.0000
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog9)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 90.0000 100.0000 90.0000 120.0000 100.0000 90.0000 90.0000
2LA-app 100.0000 100.0000 100.0000 100.0000 100.0000 90.0000 100.0000
3RA-IVC 80.0000 100.0000 70.0000 100.0000 100.0000 70.0000 70.0000
4RA-MVC 80.0000 110.0000 60.0000 110.0000 100.0000 60.0000 50.0000
5 RA-SVC 70.0000 90.0000 60.0000 80.0000 80.0000 60.0000 70.0000
6
7Mean 84.0000 100.0000 76.0000 102.0000 96.0000 74.0000 76.0000
8SD 11.4018 7.0711 18.1659 14.8324 8.9443 15.1658 19.4936
9SEM 5.0990 3.1623 8.1240 6.6332 4.0000 6.7823 8.7178
Effective Refractory Period (ERP) dispersion (disp) (2 sites, dog10)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 100.0000 110.0000 80.0000 100.0000 100.0000 80.0000 80.0000
2LA-app 120.0000 120.0000 100.0000 120.0000 120.0000 100.0000 90.0000
3RA-IVC
4RA-MVC
5RA-SVC
6
7Mean 110.0000 115.0000 90.0000 110.0000 110.0000 90.0000 85.0000
8SD 14.1421 7.0711 14.1421 14.1421 14.1421 14.1421 7.0711
9SEM 10.0000 5.0000 10.0000 10.0000 10.0000 10.0000 5.0000
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog11)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 120.0000 120.0000 110.0000 110.0000 110.0000 110.0000 110.0000
2LA-app 110.0000 120.0000 100.0000 120.0000 110.0000 120.0000 100.0000
3RA-IVC 100.0000 110.0000 80.0000 110.0000 100.0000 80.0000 80.0000
4RA-MVC 80.0000 100.0000 70.0000 110.0000 100.0000 80.0000 60.0000
5RA-SVC 80.0000 90.0000 70.0000 100.0000 90.0000 70.0000 60.0000
6
7Mean 98.0000 108.0000 86.0000 110.0000 102.0000 92.0000 82.0000
8SD 17.8885 13.0384 18.1659 7.0711 8.3666 21.6795 22.8035
9SEM 8.0000 5.8310 8.1240 3.1623 3.7417 9.6954 10.1980
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog12)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 100.0000 100.0000 100.0000 100.0000 110.0000 90.0000 90.0000
2LA-app 130.0000 130.0000 120.0000 140.0000 120.0000 110.0000 110.0000
3RA-IVC 100.0000 110.0000 100.0000 120.0000 110.0000 100.0000 90.0000
4RA-MVC 100.0000 110.0000 90.0000 120.0000 100.0000 80.0000 90.0000
5RA-SVC 90.0000 110.0000 70.0000 100.0000 100.0000 70.0000 70.0000
6
7Mean 104.0000 112.0000 96.0000 116.0000 108.0000 90.0000 90.0000
8SD 15.1658 10.9545 18.1659 16.7332 8.3666 15.8114 14.1421
9SEM 6.7823 4.8990 8.1240 7.4833 3.7417 7.0711 6.3246
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog13)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 80.0000 90.0000 80.0000 90.0000 90.0000 80.0000 80.0000
2LA-app 90.0000 90.0000 80.0000 100.0000 90.0000 70.0000 80.0000
3RA-IVC 80.0000 80.0000 70.0000 90.0000 80.0000 70.0000 70.0000
4RA-MVC 70.0000 80.0000 60.0000 80.0000 80.0000 60.0000 60.0000
5RA-SVC 60.0000 70.0000 40.0000 80.0000 70.0000 50.0000 60.0000
6
7Mean 76.0000 82.0000 66.0000 88.0000 82.0000 66.0000 70.0000
8SD 11.4018 8.3666 16.7332 8.3666 8.3666 11.4018 10.0000
9SEM 5.0990 3.7417 7.4833 3.7417 3.7417 5.0990 4.4721
Effective Refractory Period (ERP) dispersion (disp) (5 sites, dog14)
-1- -2- -3- -4- -5- -6- -7- -8-
ERPdisp Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1RA-app 130.0000 130.0000 120.0000 130.0000 120.0000 120.0000 120.0000
2LA-app 130.0000 130.0000 130.0000 130.0000 120.0000 120.0000 110.0000
3RA-IVC 110.0000 120.0000 100.0000 130.0000 120.0000 100.0000 100.0000
4RA-MVC 100.0000 120.0000 90.0000 120.0000 110.0000 90.0000 90.0000
5RA-SVC 90.0000 100.0000 80.0000 110.0000 100.0000 80.0000 80.0000
6
7Mean 112.0000 120.0000 104.0000 124.0000 114.0000 102.0000 100.0000
8SD 17.8885 12.2474 20.7364 8.9443 8.9443 17.8885 15.8114
9SEM 8.0000 5.4772 9.2736 4.0000 4.0000 8.0000 7.0711
Effects of Autonomic Nervous System on Conduction Velocity
-1- -2- -3- -4- -5- -6- -7- -8-
Dogs # Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1 2.0000 91.3000 87.3000 102.5000 90.0000 84.0000 100.0000 106.0000
2 3.0000 100.0000 101.0000 100.0000 97.0000 100.0000 102.0000 108.0000
3 4.0000 97.0000 90.0000 98.0000 87.0000 88.0000 108.0000 112.0000
4 5.0000 96.5000 88.5000 107.0000 96.0000 104.0000 111.0000 117.0000
5 6.0000 87.9000 80.0000 96.0000 82.0000 84.0000 91.0000 96.0000
6 7.0000 70.5000 70.5000 87.0000 73.0000 78.0000 86.0000 93.0000
7 8.0000 121.0000 102.0000 118.0000 94.0000 98.0000 125.0000 120.0000
8 9.0000 96.4000 86.0000 104.0000 90.0000 94.0000 111.0000 116.0000
9 11.0000 100.9000 88.0000 14.0000 84.0000 95.0000 112.0000 124.0000
10 12.0000 88.5000 76.0000 98.0000 70.0000 77.0000 108.0000 114.0000
11 13.0000 130.0000 110.0000 138.0000 104.0000 120.0000 148.0000 150.0000
12 14.0000 117.0000 102.0000 128.0000 98.0000 115.0000 124.0000 128.0000
13
14
15
16Mean 99.7500 90.1083 107.5417 88.7500 94.7500 110.5000 115.3333
17SD 16.2957 11.7344 14.5531 10.1813 13.6323 16.4510 15.0414
18SEM 4.6782 3.3874 4.2011 2.9391 3.9353 4.7490 4.3421
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.6112)
Equal Variance Test: Passed (P = 0.3313)
Group N Missing Mean Std Dev SEM
Bas 12 0 99.8 16.2 4.68
V-D 12 0 90.1 11.7 3.39
V1-S1 12 0 107.5 14.6 4.20
(V + S)-D 12 0 88.8 10.2 2.94
S-S10 12 0 94.8 13.6 3.94
V2-S1 12 0 110.5 16.5 4.75
V-S1 + S-S10 12 0 115.3 15.0 4.34
Power of performed test with alpha 0.0500:1.0000
Source of Variance DF SS MS F P
Between Subjects 11 13221.5 1202.0
Between Treatments 6 7773.5 1295.6 39.6 5.14E-020
Residual 66 2162.0 32.8
Total 83 23156.9
The differences in the mean values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = 5.14E-020). To isolate the group or groups that
differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Bonferroni's method):
Comparison Diff of Means t P < 0.05
Bas vs V-S1 + S-S10 −15.58 −6.669 Yes
Bas vs V2-S1 −10.75 −4.601 Yes
Bas vs S-S10 5.00 2.140 No
Bas vs (V + S)-D 11.00 4.708 Yes
Bas vs V1-S1 −7.79 −3.335 Yes
Bas vs V-D 9.64 4.126 Yes
V-D vs V-S1 + S-S10 −25.22 −10.796 Yes
V-D vs V2-S1 −20.39 −8.727 Yes
V-D vs S-S10 −4.64 −1.987 No
V-D vs (V + S)-D 1.36 0.581 No
V-D vs V1-S1 −17.43 −7.461 Yes
V1-S1 vs V-S1 + S-S10 −7.79 −3.335 Yes
V1-S1 vs V2-S1 −2.96 −1.266 No
V1-S1 vs S-S10 12.79 5.475 Yes
V1-S1 vs (V + S)-D 18.79 8.042 Yes
(V + S)-D vs V-S1 + S-S10 −26.58 −11.377 Yes
(V + S)-D vs V2-S1 −21.75 −9.309 Yes
(V + S)-D vs S-S10 −6.00 −2.568 No
S-S10 vs V-S1 + S-S10 −20.58 −8.809 Yes
S-S10 vs V2-S1 −15.75 −6.741 Yes
V2-S1 vs V-S1 + S-S10 −4.83 −2.069 No
Effects of Autonomic Nervous System on the Wavelength
-1- -2- -3- -4- -5- -6- -7- -8-
Dogs # Bas V-D V1-S1 (V + S)-D S-S10 V2-S1 V-S1 + S-S10
1 2.0000 9.5000 9.4000 10.0000 10.0000 9.1000 10.0000 10.2000
2 3.0000 8.5000 9.4000 7.3000 9.5000 8.8000 8.0000 8.1000
3 4.0000 11.6000 11.3000 10.3000 10.4000 9.9000 11.3000 11.2000
4 5.0000 12.0000 11.5000 12.6000 12.9000 12.5000 13.3000 12.6000
5 6.0000 8.2000 9.4000 7.7000 10.7000 7.8000 7.6000
6 7.0000 6.2000 7.6000 6.8000 7.6000 7.3000 6.6000 7.7000
7 8.0000 10.9000 10.2000 9.0000 10.0000 9.2000 9.8000 9.1000
8 9.0000 8.1000 8.6000 7.9000 9.2000 9.0000 8.2000 8.8000
9 11.0000 9.9000 9.5000 9.8000 9.2000 9.7000 10.3000 10.2000
10 12.0000 9.2000 8.5000 9.4000 8.1000 8.3000 9.7000 10.3000
11 13.0000 9.9000 9.0000 9.1000 9.2000 9.8000 9.8000 10.5000
12 14.0000 13.1000 12.2000 13.3000 12.2000 13.1000 12.6000 12.8000
13
14
15
16Mean 9.7583 9.7167 9.4333 9.9167 9.5417 9.7667 10.1364
17SD 1.9242 1.3537 1.9846 1.5183 1.7159 1.9888 1.6555
18SEM 0.5555 0.3908 0.5729 0.4383 0.4954 0.5741 0.4991
One Way Repeated Measures Analysis of Variance
Normality Test: Passed (P = 0.7307)
Equal Variance Test: Passed (P = 0.7441)
Group N Missing Mean Std Dev SEM
Bas 12 0 9.76 1.92 0.555
V-D 12 0 9.72 1.35 0.391
V1-S1 12 0 9.43 1.98 0.573
(V + S)-D 12 0 9.92 1.52 0.438
S-S10 12 0 9.54 1.72 0.495
V2-S1 12 0 9.77 1.99 0.574
V-S1 + S-S10 12 1 10.14 1.66 0.499
Power of performed test with alpha 0.0500:1.0000
The power of the performed test (0.0793) is below the desired power of 0.8000. You should interpret
the negative findings cautiously.
Source of Variance DF SS MS F P
Between Subjects 11 204.77 18.616
Between Treatments 6 2.93 0.489 1.13 0.355
Residual 65 28.10 0.432
Total 82 236.59 2.885
The differences in the mean values among the treatment groups are not great enough to exclude the
possibility that the difference is due to random sampling variability; there is not a statistically significant
difference (P = 0.355).
Expected Mean Squares:
Approximate DF-Residual = 65.0
E{MS(Subj)} = var(res) + 6.91 var(Subj)
E{MS(Treatment)} var(res) + var(Treatment)
E{MS(Residual)} = var(res)
CONCLUSION
Parasympathetic system nervous denervation significantly decreased the occurrence of atrial fibrillation. However, the activation of parasympathetic nervous system significantly increased the occurrence of atrial fibrillation and predominated the sympathetic nervous system activation effects. Local parasympathetic neurotransmitters infusion significantly increased the conversion of sustained atrial flutter to non sustained atrial fibrillation, and then to sinus rhythm. Furthermore, the local parasympathetic neurotransmitters infusion significantly reversed the effects of sotalol, a class 3 antiarrhythmic drug, on the reentry circuit characteristics during a sustained atrial flutter. This invention determined the significant effects of parasympathetic nervous system activation on the occurrence of atrial re-entrant arrhythmias. Furthermore, this invention illustrated the necessity of local ablation method of the atrial areas with the greatest density of parasympathetic innervation for the treatment of atrial arrhythmias, such as the areas near the sinoatrial nodal fat pad and septal.

Claims (9)

1. A method comprising the step of inhibiting the effects of the parasympathetic nervous system neurotransmitter release on the atria, wherein said method converting and prevents atrial flutter and fibrillation.
2. A method for significantly increasing conversion of sustained atrial flutter to non-sustained atrial fibrillation, the method comprising the step of locally infusing the a parasympathetic neurotransmitter, wherein said method significantly increases the conversion of sustained atrial flutter to non sustained atrial fibrillation on a portion of the atria via a catheter.
3. A method for significantly reversing antiarrhythmic effects of a class 3 antiarrhythmic drug, the method comprising the step of local locally infusing the a parasympathetic neurotransmitter on a portion of the atria via a catheter during a sustained atrial flutter, wherein said method significantly reverses the antiarrhythmic effects of a class 3 antiarrhythmic drug, sotalol.
4. The method, according to anyone of claims claim 2 or 3, wherein further comprising the step of infusing a parasympathetic nervous system blocker via the catheter to significantly preserves preserve the antiarrhythmic effects of a class 3 antiarrhythmic drugs drug on the occurrence of a sustained atrial re-entrant arrhythmias arrhythmia.
5. The method, according to anyone any one of claims 2 or 3, wherein further comprising infusing a parasympathetic nervous system blocker via the catheter to significantly preserves preserve the antiarrhythmic effects of class I, II, IV, V, or any other drugs used for the treatment of any of atrial re-entrant arrhythmias arrhythmia.
6. A method of treating atrial fibrillation and flutter, wherein delivering an anticholinergic agent to the myocardium significantly converts and prevents the occurrence of atrial flutter and fibrillation comprising at least one of:
a) infusing drug via the coronary arteries,
b) a direct application via drug eluting patch on the atrial epicardium,
c) a direct application via drug eluting catheter on the atrial endocardium.
7. A method, wherein catheter ablation of the atria in areas with the greatest density of parasympathetic nerve innervation significantly converts and prevents the occurrence of atrial fibrillation and flutter or other re-entrant atrial arrhythmias comprising:
inserting an electrophysiologic ablation catheter having a tip section with an ablation electrode into the right or left atrial chambers and directing the catheter to endomyocardial locations with high density of the parasympathetic fibers;
stabilizing the ablation electrode at said myocardium location;
delivering effective ablation energy through the electrode sufficient to destroy the parasympathetic nerve fibers in order to eliminate their neurotransmitter effects in the atria.
8. The method, according to claim 3 or 7, wherein catheter ablation of the atria in areas with the greatest density of parasympathetic nerve innervation significantly preserves and enhances the antiarrhythmic effects of any drugs used for the treatment of atrial arrhythmias.
9. The method according to claim 3 further comprising the step of infusing a parasympathetic nervous system blocker via the catheter to significantly preserve the antiarrhythmic effects of a class 3 antiarrhythmic drug on the occurrence of a sustained atrial re-entrant arrhythmia.
US11/046,676 2000-06-06 2005-01-28 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects Expired - Lifetime USRE42961E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/046,676 USRE42961E1 (en) 2000-06-06 2005-01-28 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/588,866 US6511500B1 (en) 2000-06-06 2000-06-06 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
US11/046,676 USRE42961E1 (en) 2000-06-06 2005-01-28 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/588,866 Reissue US6511500B1 (en) 2000-06-06 2000-06-06 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

Publications (1)

Publication Number Publication Date
USRE42961E1 true USRE42961E1 (en) 2011-11-22

Family

ID=24355624

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/588,866 Ceased US6511500B1 (en) 2000-06-06 2000-06-06 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
US11/046,676 Expired - Lifetime USRE42961E1 (en) 2000-06-06 2005-01-28 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/588,866 Ceased US6511500B1 (en) 2000-06-06 2000-06-06 Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

Country Status (1)

Country Link
US (2) US6511500B1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568399B2 (en) 2011-12-09 2013-10-29 Metavention, Inc. Methods for thermally-induced hepatic neuromodulation
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods
US12011212B2 (en) 2013-06-05 2024-06-18 Medtronic Ireland Manufacturing Unlimited Company Modulation of targeted nerve fibers
US12408974B2 (en) 2014-12-03 2025-09-09 Medtronic Ireland Manufacturing Unlimited Company Systems and methods for modulating nerves or other tissue
US12478806B2 (en) 2012-03-08 2025-11-25 Medtronic Ireland Manufacturing Unlimited Company Catheter-based devices and associated methods for immune system neuromodulation

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US7069070B2 (en) * 2003-05-12 2006-06-27 Cardiac Pacemakers, Inc. Statistical method for assessing autonomic balance
US7428436B2 (en) * 2000-11-02 2008-09-23 Cardiac Pacemakers, Inc. Method for exclusion of ectopic events from heart rate variability metrics
US6907295B2 (en) 2001-08-31 2005-06-14 Biocontrol Medical Ltd. Electrode assembly for nerve control
US7904176B2 (en) * 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
US7885709B2 (en) * 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7778711B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US8571653B2 (en) * 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7974693B2 (en) * 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
WO2003063692A2 (en) * 2002-02-01 2003-08-07 The Cleveland Clinic Foundation Delivery device for stimulating the sympathetic nerve chain
AU2003217747A1 (en) * 2002-02-26 2003-09-09 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US7885711B2 (en) * 2003-06-13 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Vagal stimulation for anti-embolic therapy
US7561922B2 (en) * 2004-12-22 2009-07-14 Biocontrol Medical Ltd. Construction of electrode assembly for nerve control
US7844346B2 (en) * 2002-05-23 2010-11-30 Biocontrol Medical Ltd. Electrode assembly for nerve control
US8204591B2 (en) * 2002-05-23 2012-06-19 Bio Control Medical (B.C.M.) Ltd. Techniques for prevention of atrial fibrillation
US7321793B2 (en) 2003-06-13 2008-01-22 Biocontrol Medical Ltd. Vagal stimulation for atrial fibrillation therapy
US7189204B2 (en) * 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
US7627384B2 (en) * 2004-11-15 2009-12-01 Bio Control Medical (B.C.M.) Ltd. Techniques for nerve stimulation
US8880192B2 (en) 2012-04-02 2014-11-04 Bio Control Medical (B.C.M.) Ltd. Electrode cuffs
US7101339B2 (en) * 2002-12-13 2006-09-05 Cardiac Pacemakers, Inc. Respiration signal measurement apparatus, systems, and methods
US8050764B2 (en) 2003-10-29 2011-11-01 Cardiac Pacemakers, Inc. Cross-checking of transthoracic impedance and acceleration signals
US7272442B2 (en) 2002-12-30 2007-09-18 Cardiac Pacemakers, Inc. Automatically configurable minute ventilation sensor
US8060197B2 (en) * 2003-05-23 2011-11-15 Bio Control Medical (B.C.M.) Ltd. Parasympathetic stimulation for termination of non-sinus atrial tachycardia
WO2004110549A2 (en) * 2003-06-13 2004-12-23 Biocontrol Medical Ltd. Applications of vagal stimulation
US7200440B2 (en) 2003-07-02 2007-04-03 Cardiac Pacemakers, Inc. Cardiac cycle synchronized sampling of impedance signal
US7887493B2 (en) * 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US8606356B2 (en) 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
WO2005028029A2 (en) * 2003-08-18 2005-03-31 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
ES2564694T3 (en) 2003-09-12 2016-03-28 Vessix Vascular, Inc. Selectable eccentric remodeling and / or ablation system of atherosclerotic material
US7392084B2 (en) * 2003-09-23 2008-06-24 Cardiac Pacemakers, Inc. Demand-based cardiac function therapy
US7092751B2 (en) * 2003-09-23 2006-08-15 Instrumentarium Corp. Detection of atrial arrhythmia
US7572226B2 (en) * 2003-10-28 2009-08-11 Cardiac Pacemakers, Inc. System and method for monitoring autonomic balance and physical activity
US7657312B2 (en) * 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US7706884B2 (en) 2003-12-24 2010-04-27 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US7509166B2 (en) 2003-12-24 2009-03-24 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US8126560B2 (en) * 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US9020595B2 (en) * 2003-12-24 2015-04-28 Cardiac Pacemakers, Inc. Baroreflex activation therapy with conditional shut off
US8396560B2 (en) * 2004-11-18 2013-03-12 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20050149129A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baropacing and cardiac pacing to control output
US8126559B2 (en) 2004-11-30 2012-02-28 Cardiac Pacemakers, Inc. Neural stimulation with avoidance of inappropriate stimulation
US7460906B2 (en) * 2003-12-24 2008-12-02 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US7869881B2 (en) * 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US20050149132A1 (en) 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US7486991B2 (en) * 2003-12-24 2009-02-03 Cardiac Pacemakers, Inc. Baroreflex modulation to gradually decrease blood pressure
US7643875B2 (en) * 2003-12-24 2010-01-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
CA2560756A1 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US7322973B2 (en) * 2004-03-31 2008-01-29 Cryocath Technologies Inc. Method and apparatus for preventing atrial fibrillation
US7260431B2 (en) * 2004-05-20 2007-08-21 Cardiac Pacemakers, Inc. Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device
DK1759536T3 (en) * 2004-06-01 2011-09-05 Kwalata Trading Ltd In vitro techniques for use with stem cells
US7747323B2 (en) 2004-06-08 2010-06-29 Cardiac Pacemakers, Inc. Adaptive baroreflex stimulation therapy for disordered breathing
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US8175705B2 (en) * 2004-10-12 2012-05-08 Cardiac Pacemakers, Inc. System and method for sustained baroreflex stimulation
US7781402B2 (en) * 2004-10-12 2010-08-24 Closed Loop Therapies Ltd. Methods and implantable devices for treating supraventricular arrhythmias
US8332047B2 (en) * 2004-11-18 2012-12-11 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US20060110374A1 (en) * 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US8609082B2 (en) 2005-01-25 2013-12-17 Bio Control Medical Ltd. Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis
US7548780B2 (en) * 2005-02-22 2009-06-16 Cardiac Pacemakers, Inc. Cell therapy and neural stimulation for cardiac repair
US7660628B2 (en) * 2005-03-23 2010-02-09 Cardiac Pacemakers, Inc. System to provide myocardial and neural stimulation
US7542800B2 (en) * 2005-04-05 2009-06-02 Cardiac Pacemakers, Inc. Method and apparatus for synchronizing neural stimulation to cardiac cycles
US8406876B2 (en) * 2005-04-05 2013-03-26 Cardiac Pacemakers, Inc. Closed loop neural stimulation synchronized to cardiac cycles
US8473049B2 (en) 2005-05-25 2013-06-25 Cardiac Pacemakers, Inc. Implantable neural stimulator with mode switching
US7493161B2 (en) * 2005-05-10 2009-02-17 Cardiac Pacemakers, Inc. System and method to deliver therapy in presence of another therapy
US7499748B2 (en) * 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
US7617003B2 (en) * 2005-05-16 2009-11-10 Cardiac Pacemakers, Inc. System for selective activation of a nerve trunk using a transvascular reshaping lead
US9861836B2 (en) 2005-06-16 2018-01-09 Biosense Webster, Inc. Less invasive methods for ablation of fat pads
US7819862B2 (en) * 2005-08-11 2010-10-26 St. Jude Medical, Atrial Fibrillation Division, Inc. Method for arrhythmias treatment based on spectral mapping during sinus rhythm
US7616990B2 (en) * 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US7570999B2 (en) 2005-12-20 2009-08-04 Cardiac Pacemakers, Inc. Implantable device for treating epilepsy and cardiac rhythm disorders
US9566447B2 (en) * 2005-12-28 2017-02-14 Cardiac Pacemakers, Inc. Neural stimulation system for reducing atrial proarrhythmia
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US8457734B2 (en) * 2006-08-29 2013-06-04 Cardiac Pacemakers, Inc. System and method for neural stimulation
EP2076193A4 (en) 2006-10-18 2010-02-03 Minnow Medical Inc Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
WO2008049087A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. System for inducing desirable temperature effects on body tissue
ES2560006T3 (en) 2006-10-18 2016-02-17 Vessix Vascular, Inc. Induction of desirable temperature effects on body tissue
US8233982B2 (en) * 2007-02-21 2012-07-31 Cardiac Pacemakers, Inc. Systems and methods for treating supraventricular arrhythmias
AU2008224943A1 (en) * 2007-03-13 2008-09-18 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20090253974A1 (en) * 2008-04-08 2009-10-08 Marc Mounir Rahme Use of tools, mapping systems, catheters, electrodes or any devices targeting any autonomic nerve(s) structure(s) in the human heart for the diagnostic, treatment and/or prevention of the recurrence of cardiac arrhythmias.
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
KR20110104504A (en) 2008-11-17 2011-09-22 미노우 메디컬, 인코포레이티드 Selective accumulation of energy according to knowledge of organizational topology
US8412338B2 (en) * 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (en) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 For the nerve cuff with bag portion without wire stimulator
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2509683B1 (en) 2009-12-08 2017-08-23 Cardiac Pacemakers, Inc. Concurrent therapy detection in implantable medical devices
EP2512330B1 (en) 2009-12-14 2024-08-14 Mayo Foundation For Medical Education And Research Device for treating cardiac disorders by modulating autonomic response
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN103068330B (en) 2010-04-09 2016-06-29 Vessix血管股份有限公司 Power generation and control devices for treating tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
WO2012100095A1 (en) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2013013156A2 (en) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
EP2734264B1 (en) 2011-07-22 2018-11-21 Boston Scientific Scimed, Inc. Nerve modulation system with a nerve modulation element positionable in a helical guide
WO2013055826A1 (en) 2011-10-10 2013-04-18 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
EP2765940B1 (en) 2011-10-11 2015-08-26 Boston Scientific Scimed, Inc. Off-wall electrode device for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
EP2768568B1 (en) 2011-10-18 2020-05-06 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
EP2768563B1 (en) 2011-10-18 2016-11-09 Boston Scientific Scimed, Inc. Deflectable medical devices
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
AU2012358143B2 (en) 2011-12-23 2015-06-11 Boston Scientific Scimed, Inc. Expandable balloon or an electrode pad with a heat sensing device
EP2797534A1 (en) 2011-12-28 2014-11-05 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
CN104540465A (en) 2012-08-24 2015-04-22 波士顿科学西美德公司 Intravascular catheter with a balloon comprising separate microporous regions
US9173696B2 (en) 2012-09-17 2015-11-03 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
WO2014047411A1 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
EP2906135A2 (en) 2012-10-10 2015-08-19 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
AU2014208379A1 (en) 2013-01-24 2015-07-23 Tylerton International Holdings Inc. Body structure imaging
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
CN105163657A (en) * 2013-03-11 2015-12-16 泰勒顿国际控股公司 Modeling the autonomous nervous system and uses thereof
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
WO2014149690A2 (en) 2013-03-15 2014-09-25 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US10426545B2 (en) 2013-04-15 2019-10-01 Mayo Foundation For Medical Education And Research Method and apparatus for percutaneous epicardial ablation of cardiac ganglionated plexi without myocardial injury
WO2014205399A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US9943365B2 (en) 2013-06-21 2018-04-17 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
AU2014284558B2 (en) 2013-07-01 2017-08-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
WO2015010074A1 (en) 2013-07-19 2015-01-22 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
EP3024405A1 (en) 2013-07-22 2016-06-01 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
EP3024406B1 (en) 2013-07-22 2019-06-19 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
JP6159888B2 (en) 2013-08-22 2017-07-05 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． Flexible circuit with improved adhesion to renal neuromodulation balloon
US9895194B2 (en) 2013-09-04 2018-02-20 Boston Scientific Scimed, Inc. Radio frequency (RF) balloon catheter having flushing and cooling capability
EP3041405A4 (en) 2013-09-08 2017-07-19 Tylerton International Inc. Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease
EP3043733A1 (en) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
WO2015057584A1 (en) 2013-10-15 2015-04-23 Boston Scientific Scimed, Inc. Medical device balloon
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
JP2016534842A (en) 2013-10-25 2016-11-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． Embedded thermocouples in denervation flex circuits
CN105899157B (en) 2014-01-06 2019-08-09 波士顿科学国际有限公司 Tear Resistant Flexible Circuit Assemblies
US10646183B2 (en) 2014-01-10 2020-05-12 Tylerton International Inc. Detection of scar and fibrous cardiac zones
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
CN105491952B (en) 2014-07-30 2020-08-04 纳维斯国际有限公司 Probe positioning
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for stimulating the vagus nerve
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
CN120078509B (en) * 2025-04-27 2025-07-04 中国人民解放军联勤保障部队第九〇〇医院 Personalized arrhythmia radiofrequency ablation system based on intelligent data analysis

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707499A (en) * 1985-12-02 1987-11-17 G. D. Searle & Co. 3-alkyl-5-(substituted amino)methyl)dihydro-3-phenyl-2(3H)-furanones and imino analogs thereof used for treatment of arrhythmia
US4886822A (en) * 1987-04-10 1989-12-12 Kowa Company, Ltd. Substituted anilide compounds which are useful in the treatment of arrhythmia
US5330507A (en) 1992-04-24 1994-07-19 Medtronic, Inc. Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
US5575766A (en) 1993-11-03 1996-11-19 Daig Corporation Process for the nonsurgical mapping and treatment of atrial arrhythmia using catheters guided by shaped guiding introducers
US5617854A (en) 1994-06-22 1997-04-08 Munsif; Anand Shaped catheter device and method
US5690681A (en) 1996-03-29 1997-11-25 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
US5919188A (en) * 1997-02-04 1999-07-06 Medtronic, Inc. Linear ablation catheter
US5954665A (en) 1995-06-07 1999-09-21 Biosense, Inc. Cardiac ablation catheter using correlation measure
US6161543A (en) 1993-02-22 2000-12-19 Epicor, Inc. Methods of epicardial ablation for creating a lesion around the pulmonary veins
US6292695B1 (en) 1998-06-19 2001-09-18 Wilton W. Webster, Jr. Method and apparatus for transvascular treatment of tachycardia and fibrillation
US6296630B1 (en) * 1998-04-08 2001-10-02 Biocardia, Inc. Device and method to slow or stop the heart temporarily
US20010044619A1 (en) * 1998-04-08 2001-11-22 Peter A. Altman Cardiac drug delivery system and method for use
US6502576B1 (en) 1997-07-08 2003-01-07 The Regents Of The University Of California Device and method for forming a circumferential conduction block in a pulmonary vein
US20090253974A1 (en) 2008-04-08 2009-10-08 Marc Mounir Rahme Use of tools, mapping systems, catheters, electrodes or any devices targeting any autonomic nerve(s) structure(s) in the human heart for the diagnostic, treatment and/or prevention of the recurrence of cardiac arrhythmias.

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707499A (en) * 1985-12-02 1987-11-17 G. D. Searle & Co. 3-alkyl-5-(substituted amino)methyl)dihydro-3-phenyl-2(3H)-furanones and imino analogs thereof used for treatment of arrhythmia
US4886822A (en) * 1987-04-10 1989-12-12 Kowa Company, Ltd. Substituted anilide compounds which are useful in the treatment of arrhythmia
US5330507A (en) 1992-04-24 1994-07-19 Medtronic, Inc. Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
US6161543A (en) 1993-02-22 2000-12-19 Epicor, Inc. Methods of epicardial ablation for creating a lesion around the pulmonary veins
US5575766A (en) 1993-11-03 1996-11-19 Daig Corporation Process for the nonsurgical mapping and treatment of atrial arrhythmia using catheters guided by shaped guiding introducers
US5617854A (en) 1994-06-22 1997-04-08 Munsif; Anand Shaped catheter device and method
US5954665A (en) 1995-06-07 1999-09-21 Biosense, Inc. Cardiac ablation catheter using correlation measure
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
US5690681A (en) 1996-03-29 1997-11-25 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US5919188A (en) * 1997-02-04 1999-07-06 Medtronic, Inc. Linear ablation catheter
US6502576B1 (en) 1997-07-08 2003-01-07 The Regents Of The University Of California Device and method for forming a circumferential conduction block in a pulmonary vein
US6296630B1 (en) * 1998-04-08 2001-10-02 Biocardia, Inc. Device and method to slow or stop the heart temporarily
US20010044619A1 (en) * 1998-04-08 2001-11-22 Peter A. Altman Cardiac drug delivery system and method for use
US6292695B1 (en) 1998-06-19 2001-09-18 Wilton W. Webster, Jr. Method and apparatus for transvascular treatment of tachycardia and fibrillation
US20090253974A1 (en) 2008-04-08 2009-10-08 Marc Mounir Rahme Use of tools, mapping systems, catheters, electrodes or any devices targeting any autonomic nerve(s) structure(s) in the human heart for the diagnostic, treatment and/or prevention of the recurrence of cardiac arrhythmias.

Non-Patent Citations (139)

* Cited by examiner, † Cited by third party
Title
Alessie, R., et al., "Nonuniform distribution of vagal effects on the atrial refractory period," Am. J. Physiol., 194:406-10 (1958).
Allessie MA, Lammers WJ, Bonke IM, and Hollen J., "Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog," Circulation. Jul. 1984;70(1):123-35.
Allessie, M., et al., "Total mapping of atrial excitation during acetylcholine-induced atrial flutter and fibrillation in the isolated canine heart," in Kulbertus, H.E., Olsson, S.B., Schlepper, M., eds., Atrial Fibrillation, Molndal, Sweden, AB Hassle, 44-61 (1982).
Arenal, A., et al., "Frequency and implications for resetting and entrainment with right atrial stimulation in atrial flutter," Am. J. Cardiol., 70:1292-8 (1992).
Avitall et al., "Physics and Engineering of Transcatheter Cardiac Tissue Ablation," Journal of American College of Cardiology 95(3), 921-32 (Sep. 1993).
Bellavere, F., et al., "Autonomic control of the immediate heart rate response to lying down," Clin. Sci. (Lond), 62(1):57-64 (1982).
Boineau, J.P., "Atrial flutter: a synthesis of concepts," Circ., 72:249-57 (1985).
Boyden P., "Models of atrial reentry," Journal of Cardiovascular Elecrophysiology, 1995;6:313-24.
Boyden, P.A., et al., "Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol," J. Cardiovasc. Electrophysiol., 4(3):266-79 (Jun. 1993).
Brown, J.H., "Cholinergic inhibition of catecholamine-stimulable cyclic AMP accumulation in murine atria," J. Cyclic Nucleotide Res., 5(6):423-33 (1979).
Campbell, T.J., "Cellular electrophysiology effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity," Br. J. Pharmacol., 90:593-99 (1987).
Campbell, T.J., et al., "Intravenous sotalol for the treatment atrial fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a randomised trial," Br. Heart J., 54:86-90 (1985).
Capucci, A., et al., "Autonomic influence and paroxysmal atrial fibrillation: results of 24-hour power spectral analysis," J. Am. Coll. Cardiol; 23(Suppl. A):252A, 914-95 (1994).
Carlson MD, Geha AS, Hsu J, Martin PJ, Levy MN, Jacobs G, Waldo AL., "Selective stimulation of parasympathetic nerve fibers to the human sinoatrial node," Circulation. Apr. 1992;85(4):1311-7.
Carlson, M.D., et al., "Differential effects of canine epicardial parasympathetic nerve stimulation on right and left atrial effective refractory periods," Circ., 80(4)(Suppl. II):598, 2374 (1989).
Carmeliet, E., "Electrophysiologic and voltage clamp analysis of the effects of Sotalol on isolated cardiac muscle and Purkinje fibers," J. Pharmacol Exp. Ther., 232:817-25 (1985).
Chandler MP, DiCarlo SE., "Sinoaortic denervation prevents postexercise reductions in arterial pressure and cardiac sympathetic tonus,", Am J. Physiol. Dec. 1997;273(6 Pt 2):H2738-45.
Chiou CW, Eble JN, and Zipes DP, "Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad.," Circulation 1997;95:2573-2584.
Coplen, S.E. et al., "Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials," Circ., 82(4):1106-16 (1990).
Coumel P, Leenhardt A., "Mental activity, adrenergic modulation, and cardiac arrhythmias in patients with heart disease," Circulation. Apr. 1991;83(4 Suppl)II58-70.
Coumel P., "Cardiac arrhythmias and the autonomic nervous system," J. Cardiovasc Electrophysiol. Jun. 1993;4(3):338-55.
Coumel, P., "Heart rate variability and the onset of tachyarrhythmias," G. Ital. Cardiol., 22(5):647-54 (1992).
Coumel, P., "Neural aspects of paroxysmal atrial fibrillation," in Falk, R.H., Podrid, P.J., eds., Atrial fibrillation: mechanisms and management, Raven Press, Ltd., New York, 109-125 (1992).
Courtney, K.R., et al., "Possible mechanisms for d-sotalol's effects on action potential duration and conduction velocity in myocardium," Proc. West Pharmacol., 33:1-4 (1990).
Crijns, H.J., et al., "Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter," Am J. Cardiol., 68:335-41 (1991).
Dalal, P., et al., "Autonomic nervous system activity before onset of paroxysmal atrial fibrillation by power spectral analysis of heart rate," J. Am. Coll. Cardiol., 23(Suppl. A):457A, 821-2 (1994).
Della Bella, P., et al., "The excitable gap of type I atrial flutter in humans," in Waldo, A.L., Touboul, P., eds., Atrial flutter: advances in mechanisms and management, Futura Pub. Co., Inc., Armonk, NY, 259-68 (1996).
Derakhchan K, Page P, Lambert C, and Kus T., "Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia," Journal of Pharmacology and Experimental Therapeutic, 1994; 270:47-54.
Disertori, M., et al., "Evidence of a reentry circuit in the common type of atrial flutter in man," Circ., 67(2):434-40 (1983).
Do, Q.B. et al., "Study for autonomic innervation of the inter-atrial septum using iso-integral cartography in dogs," Annals of Surgery, 50(8):659-66 (1996).
Duru, F., et al., "Autonomic effects of radiofrequency catheter ablation," The Europace Society of Cardiology, Europace (2000) 2, 181-185.
Eckberg DL, "Parasympathetic cardiovascular control in human disease: a critical review of methods and results," Am J. Physiol. Nov. 1980;239(5):H581-93.
Ewing, D.J., et al., "New method for assessing cardiac parasympathetic activity using 24-hour electrocardiograms," Br. Heart J., 52:396-402 (1984).
Falk, R.H., "Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial flutter," Ann. Int. Med., 111(2):107-11 (1989).
Feld ,G.K., "Atrial fibrillation: is there a safe and highly effective pharmacological treatment?," Circ., 82(6):2248-50 (1990).
Feld, G.K., et al., "Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine and lidocaine, and significance of changes in refractoriness and conduction," Cir., 74(1):197-204 (1986).
Fiset, C., et al., "Stereoselective high-performance liquid chromatographic assay for the determination of sotalol enantiomers in biological fluids," J. Chromatogr., 612:231-37 (1993).
Flaker, G., et al., "Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation," J. Am. Coll. Cardiol., 20(3):527-32 (1992).
Frame LH, Page RL, Hoffman BF., "Atrial reentry around an anatomic barrier with a partially refractory excitable gap. A canine model of atrial flutter," Circ Res. Apr. 1986;58(4):495-511.
Furukawa Y, Hoyano Y, Chiba S., "Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs," Am J. Physiol. Jul. 1996;271(1 Pt 2):H44-50.
Furukawa Y, Wallick DW, Carlson MD and Martin P., "Prolongation of cardiac cycle length attenuates negative dromotropic response to selective vagal stimuli," J Auton Nerv Syst. Oct. 1989;28(1):43-50.
Furukawa Y, Wallick DW, Carlson MD, and Martin PJ., "Cardiac electrical responses to vagal stimulation of fibers to discrete cardiac regions," Am J. Physiol. Apr. 1990;258(4 Pt 2):H1112-18.
Glickstein, J.S., et al., "Electrocardiographic repolarization abnormalities in familial dysautonomia: an indicator of cardiac autonomic dysfunction," Clinical Autonomic Research, 9(2):109-12 (1999).
Govier, W.C., et al., "Myocardial alpha and beta adrenergic receptors as demonstrated by atrial functional refractory-period changes," J. Pharmacol. Exp. Ther., 154(2):255-63 (1966).
Greene, H.L., et al., "The cardiac arrhythmia suppression trial: first CAST . . . then CAST-II," J. Am. Coll. Cardiol., 19(5):894-98 (1992).
Grubb, B.P., et al., "Clinical disorders of the autonomic nervous system associated with orthostatic intolerance : an overview of classification, clinical evaluation, and management," Pacing Clin. Electrophysiol., 22:798-810 (1999).
Haissaguerre et al., "Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation," Journal of Cardiovascular Electrophysiology 7(12), 1132-1144 (Dec. 1996).
Han, J., et al., "Adrenergic effects on ventricular vulnerability," Circ. Res., 14:516-24 (1964).
Han, J., et al., "Nonuniform recovery of excitability in ventricular muscle," Circ. Res., 14:44-60 (1964).
Hashimoto K, Chiba S, Tanaka S, Hirata M, Suzuki Y., "Adrenergic mechanism participating in induction of atrial fibrillation by ACh," Am J Physiol. Nov. 1968;215(5):1183-91.
Hedman AE, Hartikainen JE, Tahvanainen KU, Hakumaki MO., "The high frequency component of heart variability reflects cardiac parasympathetic modulation rather than parasympathetic 'tone'," Acta Physiol Scand. Nov. 1995;155(3):267-73.
Hedman AE, Tahvanainen KU, Hartikainen JE, Hakumaki MO., "Effect of sympathetic modulation and sympatho-vagal interaction on heart rate variability in anaesthetized dogs," Acta Physiol Scand. Oct. 1995;155(2):205-14.
Henning RJ, Khalil IR, and Levy MN., "Vagal stimulation attenuates sympathetic enhancement of left ventricular function," American Journal of Physiology, 1990; 258:H1470-75.
Hewett, K.W., "Membrane effects of muscarinic agonists," inRosen, M.R., Janse, M.J., Wit, A.l., eds., Cardiac electrophysiology: a textbook, Futura Pub. Co., Inc., Mount Kisco, NY, 877-88 (1990).
Hoyano Y. Furukawa Y, Kasama M, Chiba S., "Parasympathetic inhibition of sympathetic effects on atrioventricular conduction in anesthetized dogs," Am J Physiol. Oct. 1997;273(4 Pt 2):H1800-6.
Igarashi, M., et al., "Termination and reinduction of atrial flutter after moricizine and N-acetylprocainamide in the canine pericarditis model," Pacing Clin. Electrophysiol., 15(4)(Part II):528, 96 (1992).
Inoue H. Matsuo H, Takayanagi K, Murao S., "Clinical and experimental studies of the effects of atrial extrastimulation and rapid pacing on atrial flutter cycle. Evidence of macro-reentry with an excitable gap," Am J. Cardiol. Oct. 1981;48(4):623-31.
Inoue, H., et al., "Antiarrhythmia drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031," Cardiovasc. Res., 25:223-29 (1991).
Inoue, H., et al., "Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap," J. Am. Coll. Cardiol., 18:1098-1104 (1991).
Jais et al., "A focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation," Circulation 95, 572-76 (Feb. 4, 1997).
Jalife J, Moe GK., "Phasic effects of vagal stimulation on pacemaker activity of the isolated sinus node of the young cat," Circ Res. Nov. 1979;45(5):595-607.
Janes RD, Brandys JC, Hopkins DA, Johnstone DE, Murphy DA, and Armour JA., "Anatomy of human extrinsic cardiac nerves and ganglia," American Journal of Cardiology; 1986; 57:299-308.
Juul-Möller, S., et al., "Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation," Circ., 82(6):1932-39 (1990).
Kralios FA, Millar CK., "Sympathetic neural effects on regional atrial recovery properties and cardiac rhythm," Am J Physiol. Apr. 1981;240(4):H590-96.
Lazarra R, Scherlag BJ, Robinson MJ, and Samet P., "Selective in situ parasympathetic control of the canine sinoatrial and atrioventricular nodes," Circulation Research, 1973; 32:393-401.
Leclercq, J.F., et al., "Role of the autonomic nervous system in atrial arrhythmogenesis," in Waldo, A.L., Touboul, P., eds., Atrial Flutter: advances in mechanisms and management, 293-302 (1996).
Lee, L.S., et al., "The haemodynamic effect of thoracoscopic cardiac sympathectomy," Euro. J. Surg., 164(Suppl. 580):37-8 (1998).
Levy MN, Blattberg B., "Effect of vagal stimulation on the overflow of norepinephrine into the coronary sinus during cardiac sympathetic nerve stimulation in the dog," Circ Res. Feb. 1976;38(2):81-5.
Levy, M.N., et al., "Assessment of beat-by-beat control of heart rate by the autonomic nervous system: molecular biology techniques are necessary, but not sufficient," J. Cardiovasc. Electrophysiol., 4(2):183-93 (1993).
Levy, M.N., et al., "Parasympathetic control of the heart," in Randall, W.C., ed., Nervous control of cardiovascular function, Oxford University Press, NY, 68-94 (1984).
Lewis, T., "Observations upon flutter and fibrillation, Part IV: impure flutter; theory of circus movement," Heart, 7:293-345 (1920).
Lewis, T., et al., "Observations upon flutter and fibrillation, Part II: the nature of auricular flutter," Heart, 7:191-245 (1920).
Login, I.S., et al., "Adenylate cyclase in striatal cholinergic interneurons regulates acetylcholine release," Brain Research, 735(2):330-4 (1996).
Lucini, D., et al., "Analysis of initial autonomic adjustments to moderate exercise in humans," J. Hypertension, 13:1660-3 (1995).
Lurie KG, Benditt D., "Syncope and the autonomic nervous system," J Cardiovasc Electrophysiol. Aug. 1996;7(8):760-76.
McGratten, P.A., et al., "Parasympathetic effects on in vivo rat heart can be regulated through an alpha1 -adrenergic receptor," Circ. Res., 60(4):465-71 (1987).
McGratten, P.A., et al., "Parasympathetic effects on in vivo rat heart can be regulated through an α1 -adrenergic receptor," Circ. Res., 60(4):465-71 (1987).
Miyashita Y, Furukawa Y, Nakajima K, Hirose M, Kurogouchi F, Chiba S., "Parasympathetic inhibition of sympathetic effects on pacemaker location and rate in hearts of anesthetized dogs," J Cardiovasc Electrophysiol. Aug. 1999;10(8):1066-76.
Morita, Y., et al., "Influence of cerebrovascular sympathetic, parasympathetic, and sensory nerves on autoregulation and spontaneous vasomotion," Acta Physiol. Scand., 154(2):121-30 (1995).
Murphy DA, Johnstone DE, and Armour JA., "Preliminary observations on the effects of stimulation of cardiac nerves in man," Canadian Journal of Physiology and Pharmacology, 1985; 63:649-55.
Nahum, L.H., et al., "Production of auricular fibrillation by application of acetyl-β-methyl-choline chloride to localized region of the auricular surface," Am. J. Physiol., 129:P428 (1940).
Natale, A., et al., "Safety of slow pathway ablation in patients with long PR interval: further evidence of fast and slow pathway interaction," Pacing Clin. Electrophysiol., 20(6):1698-703 (1997).
Nattel, S., "Antiarrhythmic drug classifications: a critical appraisal of their history, present status, and clinical relevance," Drugs, 41(5):672-701 (1991).
Niwano, S., et al., "Characterization of the excitable gap in a functionally determined reentrant circuit: studies in the canine sterile pericarditis model of atrial flutter," Circ., 90(4):1997-2014 (1994).
Okumura, K., et al., "Atrial activation sequence during atrial flutter in the canine pericarditis model and its effects on the polarity of the flutter wave in the electrocardiogram," J. Am. Coll. Cardiol., 17(2):509-18 (1991).
Olgin JE, Sih HJ, Hanish S, Jayachandran JV, Wu J, Zheng QH, Winkle W, Mulholland GK, Zipes DP, Hutchins G., "Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation," Circulation. Dec. 8, 1998;98(23):2608-14.
Olshansky, B., et al., "Atrial flutter-update on the mechanism and treatment," PACE 15:2308-35 (1992).
Olsovsky, M.R., et al., "Selective slow pathway ablation does not alter enhancement of vagal tone on sinus and atrioventricular nodal function," Am. J. Cardiol., 78(11):1289-92 (1996).
Ortiz, J., et al., "Mechanism of atrial flutter termination by WAY-123,398, a unique class III agent," Circ., 84(Suppl.II):507, 2017 (1991).
Pagani, J.M., et al., "Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog," Circ. Res., 59(2):178-93 (1986).
Page PL, Dandan N, Savard P, Nadeau R, Armour JA, Cardinal R., "Regional distribution of atrial electrical changes induced by stimulation of extracardiac and intracardiac neural elements," J Thorac Cardiovasc Surg. Feb. 1995;109(2):377-88.
Páge, P.L., et al., "Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis," Can. J. Physiol. Pharmacol., 69:15-24 (1991).
Pauza DH, Pauziene N. Tamasauskas KA, Stropus R., "Hilum of the heart," Anat Rec., Jul. 1997;248(3):322-24.
Pauza DH, Skripka V, Pauziene N, and Stropus R., "Morphology, distribution, and variability of the epicardiac neural ganglionated subplexuses in the human heart," Anat Rec. 2000; 259(4):353-82.
Pauza DH, Skripka V. Pauziene N. Stropus R., "Anatomical study of the neural ganglionated plexus in the canine right atrium: implications for selective denervation and electrophysiology of the sinoatrial node in dog," Anat Rec., Jul. 1, 1999;255(3):271-94.
Pauza, D.H., et al., "Morphology of the intrinsic cardiac nervous system in the dog: a whole-mount study employing histochemical staining with acetylcholinesterase," Cells Tissues Organs, 172(4):297-320 (2002).
Pinto, J.M.B., et al., "Endocardial mapping of reentry around an anatomical barrier in the canine right atrium: observations during the action of the class IC agent, flecainide," J. Cardiovasc. Electrophysiol., 4(6):672-85 (1993).
Poirier, J.M., et al., "Quantitative liquid chromatographic determination of sotalol in human plasma," Ther. Drug Monit., 8(4):474-77 (1986).
Potter, E.K., "Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y," Neuroscience Lett., 83:101-06 (1987).
Prystowsky EN, Naccarelli GV, Jackman WM, Rinkenberger RL, Heger JJ, Zipes DP., "Enhanced parasympathetic tone shortens atrial refractoriness in man," Am J Cardiol. Jan, 1, 1983;51(1):96-100.
Quan KJ, Lee JH, Geha AS, Biblo LA, Van Hare GF, Mackall JA, Carlson MD., "Characterization of sinoatrial parasympathetic innervation in humans," J Cardiovasc Electrophysiol. Aug. 1999;10(8):1060-65.
Racker, D.K., et al., "Anatomy of the tricuspid annulus: circumferential myofibers as the structural basis for atrial flutter in a canine model," Circ., 84(2):841-51 (1991).
Raczak, G., et al., "Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation," J. Heart Lung Transplant, 18(5):399-406 (1999).
Rahme MM, Cotter B, Leistad E, Subudhayangkul S, Wadhwa M, Ungab G, Feld GK., "Persistence of atrial fibrillation after its induction-importance of the duration and dispersion of atrial refractoriness and electrical remodeling," J Cardiovasc Pharmacol Ther. Apr. 1999;4(2):113-120.
Rahme MM, Cotter B, Leistad E, Wadhwa MK, Mohabir R, Ford A, Eglen RM, and Feld GK., "Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation," Circulation, 1999; 100:2010-17.
Rahme, M.M., et al., "Effects of d-sotalol on the excitable gap composition in canine atrial flutter," Pacing Clin. Electrophysiol., 18(Part II):905, 437 (1995).
Rahme, M.M., et al., "Persistence of atrial fibrillation after its induction—importance of the duration and dispersion of atrial refractoriness and electrical remodeling," J. Cariovasc. Pharmacol. Therapeut., 4(2):113-20 (1999).
Rahme, M.M., et al., "Sustainment of atrial flutter-dependence on the duration of full excitability within the excitable gap," Pacing Clin. Electrophysiol., 20(4)(Part II):1216, 664 (1997).
Randall DC, Brown DR, Li SG, Olmstead ME, Kilgore JM, Sprinkle AG, Randall WC, Ardell JL., "Ablation of posterior atrial ganglionated plexus potentiates sympathetic tachycardia to behavioral stress," Am J Physiol. Sep. 1998;275(3 Pt 2):R779-87.
Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ., "Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs," Circ Res. Feb. 1988;62(2):395-410.
Rostagno, C., et al., "The onset of symptomatic atrial fibrillation and paroxysmal supraventricular tachycardia is characterized by different circadian rhythms," Am. J. Cardiol., 71:453-55 (1993).
Sanders, P., et al., "Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans" Aug. 1, 2005, Circulation 2005; 112; 789-797.
Sanguinetti, M.C., et al., "Two components of cardiac delayed rectifier K+ current," J. Gen. Physiol., 96:195-215 (1990).
Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U., "Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report," Circulation. Aug. 1991;84(2):503-11.
Singh, B.N., et al., "A third class of anti-arrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH 3474," Br. J. Pharmacol., 39:675-87 (1970).
Singh, B.N., et al., "Sotalol: a beta blocker with unique antiarrhythmic properties," Am. Heart J., 114(1):121-39 (1987).
Spinelli, W., et al., "Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents," Circ. Res., 65(6):1565-79 (1989).
Stambler, B.S., et al., "Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration: evidence of a fully excitable gap in the reentrant circuit," J. Am. Coll. Cardiol., 27(2):453-61 (1996).
Strauss, H.C., et al., "Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue," Circ. Res., 26(6):661-78 (1970).
Takei M, Furukawa Y, Narita M, Ren LM, Karasawa Y, Murakami M, and Chiba S., "Synergistic nonuniform shortening of atrial refractory period induced by autonomic stimulation," American Journal of Physiology, 1991; 261:H1988-93.
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, "Preliminary report: effect of encainide and flecainide on mortality in a randomized trial arrhythmia suppression after myocardial infarction," N. Engl. J. Med., 321(6):406-12 (1989).
Thompson GW, Levett JM, Miller SM, Hill MR, Meffert WG, Kolata RJ, Clem MF, Murphy DA, and Armour JA., "Bradycardia induced by intravascular versus direct stimulation of the vagus nerve," The Society of Thoracic Surgeons, 1998; 65:637-42.
Uchida F, Kasai A, Omichi C, Fujii E, Teramura S, Yasuda M, Nakano T., "Effect of radiofrequency catheter ablation on parasympathetic denervation: a comparison of three different ablation sites," Pacing Clin Electrophysiol. Nov. 1998;21(11 Pt 2):2517-21.
Valette, H., et al., "Canine myocardial beta-adrenergic, muscarinic receptor densities after denervation: a PET sudy," J. Nuclear Med., 36(1):140-6 (1995).
Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS, Foreman RD, and Schwartz PJ., "Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction," Circulation Research, 1991; 68:1471-81.
Varró, A., et al., "Effect of sotalol on transmembrane ionic currents responsible for repolarization in cardiac ventricular myocytes from rabbit and guinea pig," Life Sci., 49:PL-7-PL-12 (1991).
Vatner, S.F., "Sympathetic mechanisms regulating myocardial contractility in conscious animals," in Fozzard, H.A., Haber, E., eds., The Heart and Cardiovascular System, 2nd ed., Ch. 67, pp. 1709-28, Raven Press, Ltd., New York (1992).
Wallick DW, Martin PJ, Masuda Y, Levy MN., "Effects of autonomic activity and changes in heart rate on atrioventricular conduction," Am J Physiol. Oct. 1982;243(4):H523-27.
Wang, J., et al., "Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectiveness between d-Sotalol and the new antiarrhythmic drug ambasilide," Circ., 90(4):2032-40 (1994).
Warner, H.R., et al., "A mathematical model of heart rate control by sympathetic and vagus efferent information," J. Appl. Physiol., 17:349-55 (1962).
Waxman, M.B., et al., "Effects of posture, valsalva maneuver and respiration on atrial flutter rate: an effect mediated through cardiac volume," J. Am. Coll. Cardiol., 17(7):1545-52 (1991).
Waxman, M.B., et al., "Interactions between the autonomic nervous system and tachycardias man," Cardiol. Clin., 1(2):143-85 (1983).
Wells, J.L., et al., "Characterization of atrial flutter: studies in man after open heart surgery using fixed atrial electrodes," Circ., 60(3):665-73 (1979).
Williams, E.M.V., "A classification of antiarrhythmic actions reassessed after a decade of new drugs," J. Clin. Pharmacol., 24:129-47 (1984).
Yang T, Jacobstein MD, Levy MN., "Sustained increases in heart rate induced by timed repetition of vagal stimulation in dogs," Am J Physiol. Oct. 1985;249(4 Pt 2):H703-9.
Yang T, Levy MN., "The phase-dependency of the cardiac chronotropic responses to vagal stimulation as a factor in sympathetic-vagal interactions," Circ Res. Jun. 1984;54(6):703-10.
Yano, K., et al., "Effects of sympathetic and parasympathetic stimulation on the induction of atrial flutter in dogs with aseptic pericarditis," Jpn. Heart J., 32(6):811-25 (1991).
Zanesco, A., et al., "Sino-aortic denervation causes right atrial beta adrenoceptor down-regulation," J. Pharmacol. Exp. Therapeut., 280(2):677-85 (1997).
Zipes DP, Mihalick MJ, Robbins GT., "Effects of selective vagal and stellate ganglion stimulation on atrial refractoriness," Cardiovasc Res. Sep. 1974;8(5):647-55.

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114123B2 (en) 2011-12-09 2015-08-25 Metavention, Inc. Hepatic neuromodulation using fluids or chemical agents
US10064674B2 (en) 2011-12-09 2018-09-04 Metavention, Inc. Methods of modulating nerves of the hepatic plexus
US8728070B2 (en) 2011-12-09 2014-05-20 Metavention, Inc. Hepatic neuromodulation methods
US8728069B2 (en) 2011-12-09 2014-05-20 Metavention, Inc. Modulation of nerves that innervate the liver
US8758334B2 (en) 2011-12-09 2014-06-24 Metavention, Inc. Hepatic neuromodulation devices
US8876815B2 (en) 2011-12-09 2014-11-04 Metavention, Inc. Energy delivery devices for hepatic neuromodulation
US8894639B2 (en) 2011-12-09 2014-11-25 Metavention, Inc. Hepatic artery nerve modulation methods
US9005190B2 (en) 2011-12-09 2015-04-14 Metavention, Inc. Treatment of non-alcoholic fatty liver disease
US9005191B2 (en) 2011-12-09 2015-04-14 Metavention, Inc. Neuromodulation methods using balloon catheter
US9011422B2 (en) 2011-12-09 2015-04-21 Metavention, Inc. Hepatic neuromodulation to treat fatty liver conditions
US9033969B2 (en) 2011-12-09 2015-05-19 Metavention, Inc. Nerve modulation to treat diabetes
US9060784B2 (en) 2011-12-09 2015-06-23 Metavention, Inc. Hepatic denervation systems
US9089542B2 (en) 2011-12-09 2015-07-28 Metavention, Inc. Hepatic neuromodulation using microwave energy
US9089541B2 (en) 2011-12-09 2015-07-28 Metavention, Inc. Gastroduodenal artery neuromodulation
US8579891B2 (en) 2011-12-09 2013-11-12 Metavention, Inc. Devices for thermally-induced hepatic neuromodulation
US9149329B2 (en) 2011-12-09 2015-10-06 Metavention, Inc. Glucose alteration methods
US8568399B2 (en) 2011-12-09 2013-10-29 Metavention, Inc. Methods for thermally-induced hepatic neuromodulation
US9265575B2 (en) 2011-12-09 2016-02-23 Metavention, Inc. Balloon catheter neuromodulation systems
US9999461B2 (en) 2011-12-09 2018-06-19 Metavention, Inc. Therapeutic denervation of nerves surrounding a hepatic vessel
US9114124B2 (en) 2011-12-09 2015-08-25 Metavention, Inc. Modulation of nerves innervating the liver
US10070911B2 (en) 2011-12-09 2018-09-11 Metavention, Inc. Neuromodulation methods to alter glucose levels
US12029466B2 (en) 2011-12-09 2024-07-09 Medtronic Ireland Manufacturing Unlimited Company Neuromodulation for metabolic conditions or syndromes
US10543034B2 (en) 2011-12-09 2020-01-28 Metavention, Inc. Modulation of nerves innervating the liver
US10617460B2 (en) 2011-12-09 2020-04-14 Metavention, Inc. Neuromodulation for metabolic conditions or syndromes
US10856926B2 (en) 2011-12-09 2020-12-08 Metavention, Inc. Neuromodulation for metabolic conditions or syndromes
US12478806B2 (en) 2012-03-08 2025-11-25 Medtronic Ireland Manufacturing Unlimited Company Catheter-based devices and associated methods for immune system neuromodulation
US12011212B2 (en) 2013-06-05 2024-06-18 Medtronic Ireland Manufacturing Unlimited Company Modulation of targeted nerve fibers
US12408974B2 (en) 2014-12-03 2025-09-09 Medtronic Ireland Manufacturing Unlimited Company Systems and methods for modulating nerves or other tissue
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods

Also Published As

Publication number Publication date
US6511500B1 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
USRE42961E1 (en) Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
Ardell et al. Activity of in vivo atrial and ventricular neurons in chronically decentralized canine hearts
Ben-David et al. Differential response to right and left ansae subclaviae stimulation of early afterdepolarizations and ventricular tachycardia induced by cesium in dogs.
Malliani et al. Reflex increases in heart rate elicited by stimulation of afferent cardiac sympathetic nerve fibers in the cat
Hanich et al. Autonomic modulation of ventricular arrhythmia in cesium chloride-induced long QT syndrome.
WO1999065561A1 (en) Method and apparatus for transvascular treatment of tachycardia and fibrillation
Izumi et al. The peak-to-end of the T wave in the limb ECG leads reflects total spatial rather than transmural dispersion of ventricular repolarization in an anthopleurin-A model of prolonged QT interval
Euler et al. Effect of sympathetic tone on ventricular arrhythmias during circumflex coronary occlusion
Zuanetti et al. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
Spinelli et al. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open-chest dogs
James et al. Correlative electrophysiological and anatomical studies concerning the site of origin of escape rhythm during complete atrioventricular block in the dog.
Jones et al. Effects of lidocaine and verapamil on defibrillation in humans
Randall et al. Autonomic neural control of cardiac rhythm: the role of autonomic imbalance in the genesis of cardiac dysrhythmia
Drago et al. 3D transvenous radiofrequency ablation of manifest epicardial posterior-septal accessory pathways in children: Can technology innovations improve the outcome?
Frey et al. Successful treatment of idiopathic left ventricular outflow tract tachycardia by catheter ablation or minimally invasive surgical cryoablation
Martins Autonomic control of ventricular tachycardia: sympathetic neural influence on spontaneous tachycardia 24 hours after coronary occlusion.
Malfatto et al. The response to overdrive pacing of triggered atrial and ventricular arrhythmias in the canine heart.
Littmann et al. Modification of sinus node function by epicardial laser irradiation in dogs.
Patterson et al. Mechanism of prevention of sudden death by nadolol: differential actions on arrhythmia triggers and substrate after myocardial infarction in the dog
Moore et al. Sequence of atrial excitation in the dog during antegrade and retrograde activation
Inagaki et al. Intravascular parasympathetic cardiac nerve stimulation prevents ventricular arrhythmias during acute myocardial ischemia
Cinca et al. Reciprocating tachycardia using bilateral anomalous pathways: electrophysiologic and clinical implications.
D'Agrosa Cardiac arrhythmias of sympathetic origin in the dog
Liang et al. Catheter ablation of ventricular premature depolarizations originating from the mid interventricular septum: Significance of electrocardiographic morphology for predicting origin
Stramba-Badiale et al. Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system

Legal Events

Date Code Title Description
AS Assignment

Owner name: ST. JUDE MEDICAL, ATRIAL FIBRILLATION DIVISION, IN

Free format text: CHANGE OF NAME;ASSIGNOR:ST. JUDE MEDICAL, DAIG DIVISION, INC.;REEL/FRAME:017390/0356

Effective date: 20051221

FPAY Fee payment

Year of fee payment: 12